

ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

CLOVER HMO OF NEW JERSEY, INC.

NAIC Group Code	4918, 4918 (Current)(Prior)	NAIC Company Code16	6347 Employer's ID Number 38-40	57194
Organized under the Laws of	(State of Domicile or Port of En	tryNJ
Country of Domicile				,
			Is HMO Federally Qualified?	NO
Incorporated/Organized	11/21/2017		Commenced Business	01/01/2019
•	30 Montgome	ery Street, 15th Floor	Jersey City, NJ, US 07302	
Main Administrative Office			201-432-2133	
	Jersey City, IV	3, 03 07302	(Telephone)	•••••
Mail Address	30 Montgome	ery Street 15th Floor	Jersey City, NJ, US 07302	
Primary Location of Books and Records				
Records			201-432-2133	
	Jersey City, IN	5, 03 07302	(Telephone)	•••••
Internet Website Address	www.cloverbe	palth com	, , ,	
Statutory Statement Contact	Mark Herbers		201-432-2133	
			(Telephone)	
	-	nt@clovernealth.com	·····	
	(E-Mail)		(Fax)	
		OFFICERS		
Vivek Garipalli, Chie			Jamie Reynoso, Chief Op	erating Officer
Mark Herbers#, Interim	Chief Financial Of			
		OTHER		
Wendy Richey, Chief Medi			Gia Lee, General (
Rachel Fish, Chie			Andrew Toy, President & Chief	
Mark Spektor, Chie	et Medical Officer.		Sophia Chang, Chief Clinical	Informatics Officer
		DIRECTORS OR TRU		
Vivek G	•		Edward Bero	le
Justin D	oheny			
State of New Jersey				
County of Hudson		SS		
on the reporting period stated abordany liens or claims thereon, exceptionatined, annexed or referred to, entity as of the reporting period staccordance with the NAIC Annual law may differ, or, (2) that state ruto the best of their information, krincludes the related corresponding	ove, all of the here of as herein stated is a full and true tated above, and of Statement Instru ules or regulations nowledge and beli g electronic filing	in described assets were the l, and that this statement, too statement of all the assets a of its income and deductions ctions and Accounting Practs require differences in report ief, respectively. Furthermore with the NAIC, when required	they are the described officers of said absolute property of the said reporting gether with related exhibits, schedules and liabilities and of the condition and is therefrom for the period ended, and hotices and Procedures manual except to ting not related to accounting practices and the scope of this attestation by the dead, that is an exact copy (except for form ted by various regulators in lieu of or in	gentity, free and clear from and explanations therein affairs of the said reporting ave been completed in the extent that: (1) state and procedures, according escribed officers also natting differences due to
x	х		Х	
Vivek Garipalli		ark Herbers	Jaimie Reynoso	
Chief Executive Officer		terim Chief Financial Officer		cer
Subscribed and sworn to before r	ne	_	la this an original filip 22 Ves	
this			Is this an original filing? Yes	
	day of	b.	If no: 1. State the amendment number:	
	day of	b.	If no:	

ASSETS

2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3.2 Other than first lines 3.3 Infirst lines 3.2 Other than first lines 3.2 Other than first lines 3.2 Other than first lines 4.1 Properties held for sele (less \$ encumbrances) 4.2 Properties held for the production of income (less \$ encumbrances) 4.3 Properties held for sele (less \$ encumbrances) 4.3 Properties held for sele (less \$ encumbrances) 5. Cash (\$ 5.379.277, Schedule E - Part 1), cash equivalents (\$ 0.4075.636, Schedule E - Part 2) and short-term investments (\$ 3.895.027, Schedule DA) 13,349,336 13,349,349 13,349,349 13,349,349 13,349,349 13,349,349 13,349,3	ASSETS		ASSETS										
Bonda (Schalule D)					Prior Year								
Bonds (Schedule D)		1	2	3	4								
1. Bonds (Schedule D)		Assets		Assets									
2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 2.2 Common stocks 3.2 Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4.2 Properties held for the production of income (less S encumbrances) 4.2 Properties held for the production of income (less S encumbrances) 4.3 Properties held for the production of income (less S encumbrances) 4.3 Properties held for the (less S encumbrances) 4.3 Properties held for the (less S encumbrances) 5. Cash (S \$379.27Z, Schedule E- Part 1), each equivalents (S 4,075.536, Schedule 2 F- Part 2) and short-term investments (S 3.989.27Z, Schedule DA) 5. Contract loans (including S premium notes) 7. Derivatives (Schedule DB) 7. Derivatives (Schedule DB) 8. Other invested assets (Schedule DB) 8. Other invested assets (Schedule DB) 9. Receivables for securities 9. Receivables for securities 9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL) 1. Aggregate write-ins for invested assets (Schedule DL) 1. Aggregate write-ins for invested assets (Schedule DL) 1. Aggregate write-ins for jurised assets 1. Deficit (Schedule DB) 1. Aggregate write-ins for jurised assets 1. The plants less \$\$ charged off (for Title insurers only) 1. Premiums and considerations: 1. Deficit (Schedule DB) 1. The plants less \$\$ charged off (for Title insurers only) 1. Premiums and considerations: 1. The plants less \$\$ charged off (for Title insurers only) 1. Premiums and considerations: 1. Deficit (Schedule premiums and agents' balances in the course of collection 1. Schedule premiums and considerations: 1. Deficit (Schedule DB)	1. Bonds (Schedule D)												
2.2 Common stocks. 3.1 First liens. 3.2 Other than first liens. 4.2 Properties hedd for selection of income (less \$ encumbrances). 4.2 Properties hedd for selection of income (less \$ encumbrances). 4.1 Properties hedd for selection of income (less \$ encumbrances). 4.2 Properties hedd for selection of income (less \$ encumbrances). 4.3 Properties held for selection of income (less \$ encumbrances). 5. Cash (\$ \$379,772, Schedule E- Part 1), cash equivalents (\$ 40,75,536, Schedule E- Part 2) and short-term investments (\$ 3,895,9072, Schedule DA). 5. Contract loans (including \$ premium notes). 7. Derivatives (Schedule DB). 8. Derivatives (Schedule DB). 9. Previous (S	· · · · · · · · · · · · · · · · · · ·												
3. Mortgage loans on real estate (Schedule B): 3.1 First lones 3.2 Other than first liens 4.2 Properties cocupied by the company (less \$ encumbrances) 4.1 Properties occupied by the company (less \$ encumbrances) 4.2 Properties hald for saile (less \$ encumbrances) 4.3 Properties hald for saile (less \$ encumbrances) 4.4 Properties hald for saile (less \$ encumbrances) 4.5 Properties hald for saile (less \$ encumbrances) 4.6 Properties hald for saile (less \$ encumbrances) 4.7 Properties hald for saile (less \$ encumbrances) 4.8 Properties hald for saile (less \$ encumbrances) 4.9 Properties hald for saile (less \$ encumbrances) 4.1 Properties hald for saile (less \$ encumbrances) 4.2 Properties hald for saile (less \$ encumbrances) 4.3 Properties hald for saile (less \$ encumbrances) 4.4 Derivatives (Schedule BA) 5. Derivatives (Schedule BA) 6. Contract (lasns (including \$ encumbrances) 6. Receivables for securities 6. Receivables for securities 7. Receivables for securities 7. Receivables for securities 7. Receivables (encumbrance) 8. Receivables less \$ charged (five Title insurers only) 8. Less for securities 8. Support (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ charged (five Title insurers only) 8. Less for securities ses \$ c	2.1 Preferred stocks												
3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$ encumbrances) 4.2 Properties held for the production of income (less \$ encumbrances) 4.3 Properties held for sale (less \$ encumbrances) 4.4 Properties held for sale (less \$ encumbrances) 4.5 Properties held for sale (less \$ encumbrances) 4.5 Properties held for sale (less \$ encumbrances) 4.6 Properties held for sale (less \$ encumbrances) 4.7 Derivatives (Schedule DB) 4.5 Other invested assets (Schedule DA) 5. Properties oscapitate (less \$ encumbrances) 5. Securities lending reinvested ossets (Schedule DL) 5. Securities lending reinvested assets (Lines 1 to 11) 5. Especial properties of invested assets (Lines 1 to 11) 5. Especial plants less \$ charged off (for fills insurers only) 5. Investment income due and accrued 5. Premiums and considerations: 5. Line plants less \$ charged off (for fills insurers only) 5. Premiums and considerations: 5. Deferred premiums, agents balances in the course of collection. 5. Properties held by or deposited with reinsured companies 6. Securities lending \$ earned but abilities to the foreign insurance contracts as a properties properties and properties properties and properties properties properties and prop	2.2 Common stocks												
3.2. Other than first liens 4. Real estate (Schedule A) 4. Properties occupied by the company (less & encumbrances) 4.1. Properties held for the production of income (less & encumbrances) 4.2. Properties held for the production of income (less & encumbrances) 4.3. Properties held for the production of income (less & encumbrances) 5. Cash (8.87)972 Schedule Part 1), cash equivalents (\$4.075,636, Schedule E - Part 2) and short-term investments (\$3.895,027, Schedule DA) 5. Contract loans (including 8.) permium notes) 6. Contract loans (including 8.) permium notes) 7. Derivatives (Schedule DB) 8. Receivables (Schedule DB) 9. Receivables for securities 9. Receivables for securities 10. Securities lending reinvested oblateral assets (Schedule DL) 11. Aggregate write-ins for invested assets (Schedule DL) 12. Subtotals, cash and invested assets (Schedule DL) 13. Title plants less \$\$ charged off (for Title insurers only) 14. Investment income due and accrued 15. Determiting and considerations 15.1. Uncollected premiums, agents balances in the course of collection 15.2. Determiting and considerations 15.2. Determiting and despits balances in the course of collection 15.2. Determiting and considerations 15.3. Accrued premiums, agents balances and installments booked but deferred and not yet due (including \$\$ earned but unbilled premiums) 15.3. Accrued terrospective premiums (\$\$) and contracts subject to redetermination (\$\$3,517,227\$ 3,517,227\$ 1,017,947 16. Reinsurance. 16.1. Amounts recoverable from reinsurers 16.2. Funds held by or deposited with reinsured companies 16.3. Other amounts receivable under reinsurance contracts 18.2. Vet deferred and foreign income tax recoverable and interest thereon 18.1. Veterred tax asset 19. Sugranny funds receivable in order reinsurance contracts 10.2. Funds the dip by or deposited with reinsured companies 10.3. Promiting and the production of the protein protein and official tax asset 19. Sugranny funds receivable in order reinsurance contracts 10.2. Receivables from pasent, subsidia													
4. Real estate (Schedule A): 4.1 Properties occupied by the company (Jess S. encumbrances) 4.2 Properties need for the production of income (Jess S. encumbrances) 4.3 Properties held for sale (Jess S. encumbrances) 4.3 Properties held for sale (Jess S. encumbrances) 4.3 Properties held for sale (Jess S. encumbrances) 5. Cash (S. 5.379.277, Schedule E. – Part 1); and short purisher in sestiments (S. 4075,636, Schedule E. – Part 2) and short error investments (S. 3.995,027, Schedule D.) 7. Derivatives (Schedule DB) 8. Other invested assets (Schedule BA) 9. Schedule Schedule BA) 9. Schedule Schedule BA 9. Receivables for securities 9. Securities lending reinvested collateral assets (Schedule DL) 11. Aggregate write-ins for invested assets (Schedule DL) 12. Subtotals, cash and invested assets (Schedule DL) 13. Title plants Jess S. charged off (for Title Insurers only) 14. Investment income due and accrued 16. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection. 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (Including S. earned but unbilled premiums) 15.3 Accrued retrospective premiums (S.) and contracts subject to redetermination (S. 3.517.227) 10.17,94; 16. Rensurance: 16.1 Amounts recoverable from reinsurers 16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 18.1 Current federal and foreign income tax recoverable and interest thereon. 18.1 Current federal and foreign income tax recoverable and interest thereon. 18.2 Net deferred tax asset 19. Securities securities (S. 2,454,806) and other amounts receivable under reinsurance contracts 19. Securities from parent, subsidiaries and affiliates 19. Very deferred tax asset 19. Very defer	3.1 First liens												
4.1 Properties occupied by the company (less \$ encumbrances) 4.2 Properties held for the production of income (less \$ encumbrances) 4.3 Properties held for the production of income (less \$ encumbrances) 5. Cash (\$ 5379272, Schedule E- Part 1), eash equivalents (\$ 407536, Schedule 5. F-Part 2) and short-term investments (\$ 3895027, Schedule DA) 5. Contract losins (including \$ permium notes) 6. Contract losins (including \$ permium notes) 7. Derivatives (Schedule BA) 8. Other invested assets (Schedule BA) 8. Receivables for securities 8. Receivables for securities 9. Title plants less \$ charged differ lite insurers only) 1. Title plants less \$ charged off (for Title insurers only) 1. Title plants less \$ charged off (for Title insurers only) 1. Title plants less \$ charged off (for Title insurers only) 1. Title plants less \$ charged off (for Title insurers only) 1. Title plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurers only) 1. The plants less \$ charged off (for Title insurer	3.2 Other than first liens												
4.2 Properties held for stel (ses S encumbrances) 4.3 Properties held for stel (ses S encumbrances) 5. Cash (\$ 5.379.272, Schedule E - Part 1), cash aguivalents (\$ 4.075.636, Schedule E - Part 2) and short-term investments (\$ 3.895.077, Schedule DA) 6. Contract Ioans (including S premium notes) 7. Derivatives (Schedule BA) 8. Other invested assets (Schedule BA) 9.945,955 8. Other invested assets (Schedule BA) 9.945,955 9. Receivables for securities 9. Receivables for securities 9. Securities lending reinvested collateral assets (Schedule DL) 1. Aggregate write-ins for invested assets (Schedule DL) 1. Aggregate write-ins for invested assets (Schedule DL) 1. Aggregate write-ins for invested assets (Schedule DL) 1. Investment income due and accrued 1. Investment income due and accrued 1. Investment income due and accrued 1. Premiums and considerations: 1. 15.1 Uncollected premiums, agents balances in the course of collection 1. 15.2 Deferred premiums, agents balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums) 1. 15.3 Accrued etrospective premiums (S - 3.677,227) 1. 3.517,227 1. 1.017,944 1. Reinsurance: 1. 16.1 Amounts recoverable from reinsurers 1. 16.2 Funds held by or deposited with reinsured companies 1. 16.3 Other amounts receivable under reinsurance companies 1. 16.3 Other amounts receivable under reinsurance contracts 1. 2. Event federal and foreign income tax recoverable and interest thereon 1. 2. Funds and equipment, including health care delivery assets (\$) 1. Vertical deferred tax asset 1. Vertical respective to uninsured plans 1. Current federal and foreign income tax recoverable and interest thereon 1. Vertical respective premiums (\$ 2.454,806) and other amounts receivable ender reinsurance contracts 1. 2. Fund ture and equipment, including health care delivery assets (\$) 1. Vertical respective properties of the terminal properties of the respective properties of the retraction of the respective properties of the retraction of the respective prope													
4.3 Properties held for sale (less \$ encumbrances) 5. Cash (S.8.79272, Schedule E - Part 1), cash equivalents (S. 4075,636, Schedule E - Part 2) and short-term investments (S. 399,027, Schedule DA) 5. Contract loss (including S premium notes) 7. Derivatives (Schedule DB)													
5. Cash (\$ 5.379.272, Schedule E - Part 1), cash equivalents (\$ 4.075.036, Schedule E - Part 2) and short-term investments (\$ 3.895.027, Schedule DA). 5. Contract loans (Including \$ premium notes). 5. Contract loans (Including \$ premium notes). 7. Derivatives (Schedule DB). 8. Other invested assets (Schedule BA). 9. Receivables for securities. 9. Receivables for securities. 10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets. 12. Subtotals, cash and invested assets. 13. Title plants less \$ charged off (for Title insurers only). 13. Title plants less \$ charged off (for Title insurers only). 14. Investment income due and accused. 15. Permiums and considerations: 15. 1 Uncollected premiums, agents' balances in the course of collection. 15. 2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15. 3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3.517.227). 16. Reinsurance: 16. 1 Amounts receivable under reinsurers. 16. 2 Funds held by or deposted with reinsured companies. 16. 3 Other amounts receivable under reinsurers. 16. 2 Funds held by or deposted with reinsured companies. 16. 3 Other amounts receivable under reinsurers. 16. 2 Funds held by or deposted with reinsured companies. 16. 3 Other amounts receivable under reinsurers. 16. 2 Funds held by or deposted with reinsured companies. 16. 3 Other amounts receivable under reinsurers. 16. 4 Funds held by or deposted with reinsured companies. 16. 5 Other amounts receivable under reinsurers. 16. 1 Funds held by or deposted with reinsured companies. 16. 2 Funds held by or deposted with reinsured. 18. 1 Current federal and foreign income tax recoverable and interest thereon. 18. 1 Current federal and foreign income tax recoverable and interest thereon. 18. 1 Current federal and foreign income tax recoverable and interest thereon. 18. 2 Val deferred tax asset. 19.													
E - Part 2 and short-term investments (\$ 3,895,027, Schedule DA) 13,349,936 15,349,936 15,349,936 9,945,955 Contract longs (including 5) premium notes) 7. Derivatives (Schedule DB) 7. Derivatives (Sc													
7. Derivatives (Schedule DB)	E - Part 2) and short-term investments (\$ 3,895,027, Schedule DA)	13,349,936											
3. Other invested assets (Schedule BA) 4,561,790 4,561,790 3,047,091 8,000													
10. Securities lending reinvested collateral assets (Schedule DL)													
11. Aggregate write-ins for invested assets													
12. Subtotals, cash and invested assets (Lines 1 to 11) 28,259,685 28,259,685 15,924,011 13. Title plants less \$ charged off (for Title insurers only) 12,792 12,792 7,564 14. Investment income due and accrued 12,792 12,792 7,564 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 208,820 56,230 152,590 56,844 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$E earmed but unbilled premiums) 15.3 Accrued retrospective premiums (\$E													
13. Title plants less \$ charged off (for Title insurers only). 12,792 12,792 7,566	11. Aggregate write-ins for invested assets	20.050.605		00.050.605	45004047								
14. Investment income due and accrued 12,792 7,566													
15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3,517,227 3,517,227 3,517,227 3,517,227 1,017,942 1,017,942 1,017,942 1,017,942 1,017,943 1,0													
15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3,517,227). 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3,517,227). 16. Reinsurance: 16.1 Amounts recoverable from reinsurers. 16.2 Funds held by or deposited with reinsured companies. 16.3 Other amounts receivable under reinsurance contracts. 16.3 Other amounts receivable endating to uninsured plans. 16.1 Current federal and foreign income tax recoverable and interest thereon. 18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit. 20. Electronic data processing equipment and software. 21. Furniture and equipment, including heelth care delivery assets (\$). 22. Net adjustment in assets and liabilities due to foreign exchange rates. 23. Receivables from parent, subsidiaries and affiliates. 24. Health care (\$ 2,454,806) and other amounts receivable. 25. Aggregate write-ins for other-than-invested assets. 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected. 27. Form Separate Accounts, Segregated Accounts and Protected. 28. Total (Lines 26 and 27). 36,557,636 36,557,636 37,5521,972 36,557,636 37,5521,972 37,5521,972 38,5		12,/92		12,/92	/,566								
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3,517,227). 16. Reinsurance: 16.1 Amounts recoverable from reinsurers. 16.2 Funds held by or deposited with reinsured companies. 16.3 Other amounts receivable under reinsurence contracts. 16.4 Amounts receivable render reinsurence contracts. 16.5 Other amounts receivable under reinsurence contracts. 16.1 Amounts receivable relating to uninsured plans. 16.2 Net agnetic effect of a contract of the second of the s		200 020	FC 220	150 500	FC 0.4C								
redetermination (\$ 3,517,227)	15.2 Deferred premiums, agents' balances and installments booked but deferr	ed											
16.1 Amounts recoverable from reinsurers 16.2 Funds held by or deposited with reinsured companies. 16.3 Other amounts receivable under reinsurance contracts. 824 824 825 17. Amounts receivable relating to uninsured plans 826 18.1 Current federal and foreign income tax recoverable and interest thereon. 82. Net deferred tax asset. 83. Net deferred tax asset. 84. Burranty funds receivable or on deposit. 85. Electronic data processing equipment and software. 86. Electronic data processing equipment and software. 87. Furniture and equipment, including health care delivery assets (\$) 88. Exceivables from parent, subsidiaries and affiliates. 88. Exceivables from parent, subsidiaries and affiliates. 88. Aggregate write-ins for other-than-invested assets. 88. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 88. From Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 88. Total (Lines 26 and 27) 89. Summary of remaining write-ins for Line 11 from overflow page. 80. Totals Summary of remaining write-ins for Line 25 from overflow page. 80. Summary of remaining write-ins for Line 25 from overflow page. 81. Summary of remaining write-ins for Line 25 from overflow page. 82. Summary of remaining write-ins for Line 25 from overflow page. 83. Summary of remaining write-ins for Line 25 from overflow page.	15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$ 3,517,227)	3,517,227		3,517,227	1,017,942								
16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software 21. Furniture and equipment, including health care delivery assets (\$) 22. Net adjustment in assets and liabilities due to foreign exchange rates 23. Receivables from parent, subsidiaries and affiliates 24. Health care (\$ 2,454,806) and other amounts receivable 25. Aggregate write-ins for other-than-invested assets 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 28. Total (Lines 26 and 27) 29. Total (Lines 26 and 27) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts and Protected Cell Accounts (Lines 12 to 25) 30. Separate Accounts, Segregated Accounts and Protected Cell Accounts													
16.3 Other amounts receivable under reinsurance contracts 824 824 824 824 824 824 824 824 824 824													
17. Amounts receivable relating to uninsured plans 1,086,905													
18.1 Current federal and foreign income tax recoverable and interest thereon.													
18.2 Net deferred tax asset	17. Amounts receivable relating to uninsured plans	1,086,905		1,086,905									
19. Guaranty funds receivable or on deposit. 20. Electronic data processing equipment and software. 21. Furniture and equipment, including health care delivery assets (\$) 22. Net adjustment in assets and liabilities due to foreign exchange rates 23. Receivables from parent, subsidiaries and affiliates 46,003 8,862 37,141 1,500,000 24. Health care (\$ 2,454,806) and other amounts receivable 3,424,183 969,376 2,454,806 2,129,216 25. Aggregate write-ins for other-than-invested assets 1,196 1,196 - 20,454,806 2,129,216 20,212,216 2													
Electronic data processing equipment and software													
21. Furniture and equipment, including health care delivery assets (\$)													
Net adjustment in assets and liabilities due to foreign exchange rates 23. Receivables from parent, subsidiaries and affiliates 46,003 8,862 37,141 1,500,000 24. Health care (\$ 2,454,806) and other amounts receivable 3,424,183 969,376 2,454,806 2,129,216 25. Aggregate write-ins for other-than-invested assets 1,196 1,196 -													
23. Receivables from parent, subsidiaries and affiliates													
24. Health care (\$ 2,454,806) and other amounts receivable 3,424,183 969,376 2,454,806 2,129,216 25. Aggregate write-ins for other-than-invested assets 1,196 1,196 — 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) 36,557,636 1,035,664 35,521,972 20,635,587 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts 36,557,636 1,035,664 35,521,972 20,635,587 28. Total (Lines 26 and 27) 36,557,636 1,035,664 35,521,972 20,635,587 20 tetails of Write-Ins 1101 1102 1103 11102 11102 11103 11103 11103 11104 11104 11104 11104 11104 11104 11104 11104 11105 11106<	·												
25. Aggregate write-ins for other-than-invested assets													
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)													
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts. 28. Total (Lines 26 and 27)	26. Total assets excluding Separate Accounts, Segregated Accounts and Protected												
28. Total (Lines 26 and 27) 36,557,636 1,035,664 35,521,972 20,635,587 Details of Write-Ins 1101. 1102. 1103. 1198. Summary of remaining write-ins for Line 11 from overflow page. 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above) 1,196 1,196 - 2502. 2503. 2598. Summary of remaining write-ins for Line 25 from overflow page.													
Details of Write-Ins 1101	· · · · · · · · · · · · · · · · · · ·												
1101	Details of Write-Ins	, ,	,,	, ,	.,,								
1102. 1103. 1198. Summary of remaining write-ins for Line 11 from overflow page. 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above). 2501. Other Miscellaneous Assets. 2502. 2503. 2598. Summary of remaining write-ins for Line 25 from overflow page.													
1103. 1198. Summary of remaining write-ins for Line 11 from overflow page													
1198. Summary of remaining write-ins for Line 11 from overflow page													
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)													
2501. Other Miscellaneous Assets													
2502. 2503. 2598. Summary of remaining write-ins for Line 25 from overflow page													
2503. 2598. Summary of remaining write-ins for Line 25 from overflow page			-										
2598. Summary of remaining write-ins for Line 25 from overflow page													

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAPITAL AN	<u> </u>	Prior Year		
		1	Current Year 2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$ reinsurance ceded)			11,020,983	
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses				
4.	Aggregate health policy reserves including the liability of \$ for medical loss				
	ratio rebate per the Public Health Service Act.	6,878,609		6,878,609	1,203,383
5.	Aggregate life policy reserves				
6.	Property/casualty unearned premium reserves				
7.	Aggregate health claim reserves				
8.	Premiums received in advance				
9.	General expenses due or accrued				
10.1	Current federal and foreign income tax payable and interest thereon (including				
	\$ on realized capital gains (losses))				
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated				
14.	Borrowed money (including \$ current) and interest thereon \$ (including \$ current)				
15.	Amounts due to parent, subsidiaries and affiliates				
16.	Derivatives				
17.	Payable for securities				
18.	Payable for securities lending				
19.	Funds held under reinsurance treaties (with \$ authorized reinsurers, \$ unauthorized reinsurers and \$ certified reinsurers)				
20.	Reinsurance in unauthorized and certified (\$) companies				
21.	Net adjustments in assets and liabilities due to foreign exchange rates				
22.	Liability for amounts held under uninsured plans				
23.	Aggregate write-ins for other liabilities (including \$ current)				
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock				
27.	Preferred capital stock	XXX	XXX		
28.	Gross paid in and contributed surplus	XXX	XXX	38,318,339	17,268,339
29.	Surplus notes	XXX	XXX		
30.	Aggregate write-ins for other-than-special surplus funds	XXX	XXX		
31.	Unassigned funds (surplus).	XXX	XXX	(22,944,666)	(6,052,150
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26 \$)	XXX	XXX		
	32.2 shares preferred (value included in Line 27 \$)	XXX	XXX		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	15,373,683	11,216,199
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	35,521,972	20,635,587
Detai	ls of Write-Ins				
2301					
2302					
2303					
2398	. Summary of remaining write-ins for Line 23 from overflow page				
2399	. Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)				
2501		XXX	XXX		
2502		XXX	XXX		
2503		XXX	XXX		
2598	. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX		
	. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)		XXX		
		1	XXX		
			XXX		
			XXX		
	Summary of remaining write-ins for Line 30 from overflow page		XXX		
	. Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)		XXX		

STATEMENT OF REVENUE AND EXPENSES

		Curren	t Year	Prior Year
		1	2	3
		Uncovered	Total	Total
	Member Months.			
	Net premium income (including \$ non-health premium income)			
3.	Change in unearned premium reserves and reserve for rate credits	XXX		
4.	Fee-for-service (net of \$ medical expenses)	XXX		
	Risk revenue			
6.	Aggregate write-ins for other health care related revenues	XXX		
7.	Aggregate write-ins for other non-health revenues	XXX		
8.	Total revenues (Lines 2 to 7)	XXX	74,089,498	53,816,315
	tal and Medical:			
9.	Hospital/medical benefits		49,516,861	29,718,156
10.	Other professional services		3,110,551	1,908,680
11.	Outside referrals		13,474,899	10,022,734
12.	Emergency room and out-of-area		2,559,213	1,895,697
	Prescription drugs			
14.	Aggregate write-ins for other hospital and medical		115,103	4,843
	Incentive pool, withhold adjustments and bonus amounts			
	Subtotal (Lines 9 to 15)			
Less:	` '			
17.	Net reinsurance recoveries.			
	Total hospital and medical (Lines 16 minus 17)			
	Non-health claims (net)			
	Claims adjustment expenses, including \$ 1,061,600 cost containment expenses			
	General administrative expenses			
22.	Increase in reserves for life and accident and health contracts (including \$\) increase in reserves			
	for life only)		5,537,956	(2,006,173)
23.	Total underwriting deductions (Lines 18 through 22)		91,786,835	54,366,360
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	(17,697,337)	(550,045)
	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
	Net realized capital gains (losses) less capital gains tax of \$			
	Net investment gains (losses) (Lines 25 plus 26)			
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$) (amount charged off \$)]			
	Aggregate write-ins for other income or expenses			
	• • •			, ,
	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	(17,767,214)	(433,994)
	Federal and foreign income taxes incurred			
	Net income (loss) (Lines 30 minus 31)			
Detail	s of Write-Ins		Ì	, ,
0601.		XXX		
0602.		XXX		
0603.		XXX		
0698.	Summary of remaining write-ins for Line 6 from overflow page	XXX		
	Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)			
		1001		
		XXX		
	Summary of remaining write-ins for Line 7 from overflow page			
	Totals (Lines 0701 through 0703 plus 0798) (Line 7 above)			
	Other Medical Expenses.			
	Other Medical Expenses			
	Summary of remaining write-ins for Line 14 from overflow page			
	Totals (Lines 1401 through 1403 plus 1498) (Line 14 above)			4843
	Miscellaneous Income			(36,755)
	ivits cellatieous income			(30,733)
/411/				
		l	1	
2903.	Summary of remaining write-ins for Line 29 from overflow page			

STATEMENT OF REVENUE AND EXPENSES (CONTINUED)

		1	2
	CAPITAL & SURPLUS ACCOUNT	Current Year	Prior Year
33.	Capital and surplus prior reporting year	11,216,199	8,139,944
34.	Net income or (loss) from Line 32	(17,767,214)	(433,994
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	1,514,691	1,781,111
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets	(639,993)	130,214
40.	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock		
42.	Change in surplus notes		
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in		
	44.2 Transferred from surplus (Stock Dividend)		
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	21.050.000	1.500.000
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus		
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting year (Line 33 plus 48)		
Deta	nils of Write-Ins	, , , , , , , , , , , , , , , , , , , ,	, ,
	1. Prior Year Correction(s)		98.924
	2		
	3		
	8. Summary of remaining write-ins for Line 47 from overflow page		
	9. Totals (Lines 4701 through 4703 plus 4798) (Line 47 above)		

CASH FLOW

		1	2
		Current Year	Prior Year
	Cash from Operations		
	Premiums collected net of reinsurance	71,574,684	53,099,638
	Net investment income	2,031	95,472
	Miscellaneous income		
١.	Total (Lines 1 to 3)		
i.	Benefit and loss related payments		
٠.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
	Commissions, expenses paid and aggregate write-ins for deductions		
3.	Dividends paid to policyholders		
).	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)		
0.	Total (Lines 5 through 9)		
1.	Net cash from operations (Line 4 minus Line 10)		
١.	Cash from Investments	(13,234,007)	(2,000,010
2.	Proceeds from investments sold, matured or repaid:		
۷.	·	0 1 40 771	E 201 066
	12.1 Bonds		
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		•
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	2,148,771	5,543,912
3.	Cost of investments acquired (long-term only):		
	13.1 Bonds	9,642,900	7,260,418
	13.2 Stocks		
	13.3 Mortgage loans		
	13.4 Real estate		
	13.5 Other invested assets		
	13.6 Miscellaneous applications.	–	
	13.7 Total investments acquired (Lines 13.1 to 13.6)	9,642,900	7,260,418
4.	Net increase (decrease) in contract loans and premium notes.		
5.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(7,494,128)	(1,716,506
	Cash from Financing and Miscellaneous Sources		
6.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		
7.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		
٠.	Reconciliation of Cash, Cash Equivalents and Short-Term Investments	24,132,779	(003,002
8.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	3 403 004	/5 NNQ 100
		3,403,904	(3,006,198
9.	Cash, cash equivalents and short-term investments:	0.045.050	1405415
	19.1 Beginning of year.		
	19.2 End of year (Line 18 plus Line 19.1) Supplemental disclosures of cash flow information for non-cash transactions:	13,349,936	9,945,952

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non- Health
1. Net premium income	74,089,498						74,089,498			
2. Change in unearned premium reserves and reserve for rate credit										
3. Fee-for-service (net of \$ medical expenses)										XXX
4. Risk revenue										XXX
5. Aggregate write-ins for other health care related revenues										XXX
6. Aggregate write-ins for other non-health care related revenues		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
7. Total revenues (Lines 1 to 6)	74,089,498						74,089,498			
8. Hospital/medical benefits	49,516,861						49,516,861			XXX
9. Other professional services	3,110,551						3,110,551			XXX
10. Outside referrals	13,474,899						13,474,899			XXX
11. Emergency room and out-of-area	2,559,213						2,559,213			XXX
12. Prescription drugs	6,241,360						6,241,360			XXX
13. Aggregate write-ins for other hospital and medical	115,103						115,103			XXX
14. Incentive pool, withhold adjustments and bonus amounts										XXX
15. Subtotal (Lines 8 to 14)	75,017,987						75,017,987			XXX
16. Net reinsurance recoveries										XXX
17. Total hospital and medical (Lines 15 minus 16)	75,017,987						75,017,987			XXX
18. Non-health claims (net)		XXX	xxx	XXX	XXX	XXX	XXX	XXX	xxx	
19. Claims adjustment expenses including \$ 1,061,600 cost containment expenses							1,809,334			
20. General administrative expenses	9,421,558						9,421,558			
21. Increase in reserves for accident and health contracts							5,537,956			XXX
22. Increase in reserves for life contracts	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	XXX	XXX	XXX	XXX	XXX	XXX	XXX	xxx	
23. Total underwriting deductions (Lines 17 to 22)	91,786,835						91,786,835			
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	(17,697,337)						(17,697,337)			
Details of Write-Ins	(17,057,007)						(17,057,007)			
0501.										XXX
0502.										XXX
0503.										XXX
0598. Summary of remaining write-ins for Line 5 from overflow page										XXX
0598. Summary of femalising white-ins for Line 5 from overflow page										XXX
		XXX	VVV	VVV	VVV	XXX	XXX	XXX	XXX	
0601.			XXX	XXX	XXX					
0602.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698. Summary of remaining write-ins for Line 6 from overflow page		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
1301. Other Medical	115,103						115,103			XXX
1302.										XXX
1303.										XXX
1398. Summary of remaining write-ins for Line 13 from overflow page										XXX
1399. Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)	115,103						115,103			XXX

7

PART 1 - PREMIUMS

		1	2	3	4
	Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1+2-3)
1. Comprehe	ensive (hospital and medical)				
Medicare	Supplement				
Dental onl	ly				
4. Vision onl	ly				
Federal Er	mployees Health Benefits Plan				
6. Title XVIII	- Medicare	74,128,375			74,089,498
7. Title XIX -	- Medicaid				
8. Other heal	lth				
9. Health sub	btotal (Lines 1 through 8)	74,128,375			74,089,498
10. Life					
11. Property/o	casualty				
12. Totals (Lir	nes 9 to 11)	74,128,375			74,089,498

PART 2 – CLAIMS INCURRED DURING THE YEAR

		PART 2 - CLA	IMS INCURRED DU	RING THE YEAR	₹						
		1	2	3	4	5	6	7	8	9	10
							Federal				
			Comprehensive				Employees				
			(Hospital &	Medicare			Health	Title XVIII	Title XIX		Other Non-
		Total	Medical)		Dental Only	Vision Only		Medicare	Medicaid	Other Health	Health
1	Payments during the year:		,		,						
	1.1 Direct	72,460,704						72,460,704			
	1.2 Reinsurance assumed										
	1.3 Reinsurance ceded										
	1.4 Net.	72,460,704						72,460,704			
2.	Paid medical incentive pools and bonuses.	, ,						, , .			l
3.	Claim liability December 31, current year from Part 2A:										
	3.1 Direct	11,020,983						11,020,983			l [!]
	3.2 Reinsurance assumed										l [!]
	3.3 Reinsurance ceded										l
	3.4 Net	11,020,983						11,020,983			
4.	Claim reserve December 31, current year from Part 2D:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,									
	4.1 Direct										l [!]
	4.2 Reinsurance assumed										
	4.3 Reinsurance ceded										
	4.4 Net										l
5.	Accrued medical incentive pools and bonuses, current year										l
6.	Net health care receivables (a)							901,761			l
7.	Amounts recoverable from reinsurers December 31, current year	,									
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	7,561,938						7,561,938			l [!]
	8.2 Reinsurance assumed										
	8.3 Reinsurance ceded										
	8.4 Net.	7,561,938						7,561,938			l [!]
9.	Claim reserve December 31, prior year from Part 2D:							, ,			1
	9.1 Direct										
	9.2 Reinsurance assumed										
	9.3 Reinsurance ceded										
	9.4 Net		***************************************								
10.	Accrued medical incentive pools and bonuses, prior year										
11.	Amounts recoverable from reinsurers December 31, prior year										
12.	Incurred benefits:										
	12.1 Direct	75,017,987	***************************************					75,017,987			
	12.2 Reinsurance assumed										
	12.3 Reinsurance ceded										
	12.4 Net							75,017,987			
13.	Incurred medical incentive pools and bonuses							.,,,			
	valudas Č. Japan av advanaga ta maviidava nat vat ayrangad			1	l		1			l	

⁽a) Excludes \$ loans or advances to providers not yet expensed.

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	PARI ZA - CLAII	MS LIABILITY END (JF CURRENT YE	EAR						
	1	2	3	4	5	6	7	8	9	10
						Fadanal				ĺ
		0				Federal				İ
		Comprehensive	Madiaara			Employees Health	Title VVIII	Title XIX		Other Nen
	Total	(Hospital and	Medicare	Dontal Only	Vision Only		Title XVIII		Oth or I loolth	Other Non-
1 December 1: December 1 All advants	Total	Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Health
Reported in Process of Adjustment:										İ
1.1 Direct							4,338,792			
1.2 Reinsurance assumed										
1.3 Reinsurance ceded										
1.4 Net	4,338,792						4,338,792			
2. Incurred but Unreported:										İ
2.1 Direct	6,682,190						6,682,190			
2.2 Reinsurance assumed										
2.3 Reinsurance ceded										l
2.4 Net							6.682.190			1
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct										İ
3.2 Reinsurance assumed										1
3.3 Reinsurance ceded										
3.4 Net										
	11 000 000						11 000 000			1
4.1 Direct	' '						11,020,983			
4.2 Reinsurance assumed										
4.3 Reinsurance ceded										***************************************
4.4 Net	11,020,983						11,020,983			

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR-NET OF REINSURANCE

_		i	OF CENTION OF THE PROPERTY OF				T .
				Claim Reserve and Claim		5	6
		Claims Paid D	uring the Year	Currer	nt Year		
		1 2		3	4		
							Estimated Claim Reserve
			On Claims Incurred During		On Claims Incurred During	Claims Incurred in Prior	and Claim Liability
	Line of Business	January 1 of Current Year	the Year	December 31 of Prior Year	the Year	Years (Columns 1 + 3)	December 31 of Prior Year
1.	Comprehensive (hospital and medical)						
2.	Medicare Supplement						
3.	Dental Only						
4.	Vision Only						
5.	Federal Employees Health Benefits Plan						
6.	Title XVIII - Medicare	9,393,911	63,066,792	465,298	10,555,685	9,859,209	7,561,937
7.	Title XIX - Medicaid						
8.	Other health						
9.	Health subtotal (Lines 1 to 8)	9,393,911	63,066,792	465,298	10,555,685	9,859,209	7,561,937
10.	Health care receivables (a)						2,522,422
11.	Other non-health						
12.	Medical incentive pools and bonus amounts						
13.	Totals (Lines 9-10+11+12)				10,555,685	9,542,167	5,039,515

⁽a) Excludes \$ loans or advances to providers not yet expensed.

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

GRAND TOTAL

Section A - Paid Health Claims

		Cumulative Net Amounts Paid								
		1	2	3	4	5				
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021				
1.	Prior									
2.	2017									
3.	2018	XXX								
4.	2019	xxx	xxx	20,132	24,108	24,105				
5.	2020	xxx	xxx	xxx	41,708	50,974				
6.	2021	XXX	XXX	XXX	XXX	62,296				

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	y, Claim Reserve and Medica	Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018	XXX				
4.	2019	xxx	xxx	25,316	24,190	24,149
5.	2020	xxx	xxx	xxx	49,189	51,396
6.	2021	XXX	XXX	XXX	XXX	72,851

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019	24,358	24,105	1,456	6.038	25,561	104.938	44	1	25,606	105.123
4.	2020	53,816	50,974	1,702	3.338	52,676	97.881	421	16	53,113	98.694
5.	2021	74,089	62,296	1,418	2.277	63,714	85.996	10,556	401	74,670	100.784

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

HOSPITAL & MEDICAL

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	xxx		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019										
4.	2020										
5.	2021										

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

MEDICARE SUPPLEMENT

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	xxx		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1) Percent
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	· · · · · · · · · · · · · · · · · · ·	··· <u>·</u>	<u></u>							
2.	2018										
3.	2019										
4.	2020										
5.	2021										

12.D0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

DENTAL ONLY

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	xxx		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019										
4.	2020										
5.	2021										

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted) VISION ONLY

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	xxx		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
						Claim and				Total Claims	
						Claim				and Claims	
				Claim Adjustment		Adjustment Expense			Unpaid Claims	Adjustment Expense	
		Premiums	Claims	Expense	(Col. 3/2)	Payments	(Col. 5/1)	Claims	Adjustment	Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018.										
3.	2019										
4.	2020										
5.	2021										

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

FEDERAL EMPLOYEES HEALTH BENEFITS PLAN

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	y, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018		(
3.	2019										
4.	2020										
5.	2021										

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

TITLE XVIII MEDICARE

Section A - Paid Health Claims

			(Cumulative Net Amounts Paid		
		1	2	3	4	5
Year in Which Losses	Were Incurred	2017	2018	2019	2020	2021
1. Prior						
2. 2017						
3. 2018		xxx				
4. 2019		xxx	XXX	20,132	24.108	24.105
5. 2020		XXX	XXX	XXX	41,708	50,974
6. 2021		XXX	XXX	XXX	XXX	62,296

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	y, Claim Reserve and Medical I	ncentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018	xxx				
4.	2019	xxx	xxx	25,316	24.190	24.149
5.	2020	xxx	xxx	XXX	49,189	51,396
6.	2021	XXX	XXX	XXX	XXX	72,851

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019	24,358	24,105	1,456	6.038	25,561	104.938	44		25,606	105.123
4.	2020	53,816	50,974	1,702	3.338	52,676	97.881	421	16	53,113	98.694
5.	2021	74,089	62,296	1,418	2.277	63,714	85.996	10,556	401	74,670	100.784

12.X

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

TITLE XIX MEDICAID

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	xxx		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019										
4.	2020										
5.	2021										

12.0T

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

OTHER HEALTH

Section A - Paid Health Claims

			(Cumulative Net Amounts Pai	d	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018					
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims

		Sum of Cumulative Net Am	ount Paid and Claim Liability	y, Claim Reserve and Medica	al Incentive Pool and Bonuses	Outstanding at End of Year
		1	2	3	4	5
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1.	Prior					
2.	2017					
3.	2018		_			
4.	2019		XXX			
5.	2020	XXX	XXX	XXX		
6.	2021	XXX	XXX	XXX	XXX	

		1	2	3	4	5	6	7	8	9	10
		Premiums	Claims	Claim Adjustment Expense	(Col. 3/2)	Claim and Claim Adjustment Expense Payments	(Col. 5/1)	Claims	Unpaid Claims Adjustment	Total Claims and Claims Adjustment Expense Incurred	(Col. 9/1)
	Years in which Premiums were Earned and Claims were Incurred	Earned	Payments	Payments	Percent	(Col. 2+3)	Percent	Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019										
4.	2020										
5.	2021										

_

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	ENT AND HEALTH (
1	2	3	4	5	6	7	8	9
Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other
Total	Wicardary	опристен	Derital Olly	Violon only	Deficito Fidir	Wicaldare	Wicaldala	Other
						6,617,956		
						260,653		
						6,878,609		
						6,878,609		
		Comprehensive (Hospital & Medical) 6,617,956 260,653 6,878,609 6,878,609	Comprehensive (Hospital & Medicare Supplement	Comprehensive (Hospital & Medicare Supplement Dental Only Dental Only Supplement Dental Only Dental Only Supplement Dental Only Dental Only Dental Only Dental Only Supplement Dental Only	Comprehensive (Hospital & Medicare Supplement Dental Only Vision Only	Comprehensive (Hospital & Medicare Supplement Dental Only Vision Only Benefits Plan 6,617,956 260,653 6,878,609 6,878,609	Comprehensive (Hospital & Medicare Supplement Dental Only Vision Only Health Benefits Plan Medicare Medicare Dental Only Vision Only Medicare Med	Comprehensive (Hospital & Medicare Supplement Dental Only Vision Only Benefits Plan Title XVIII Medicare Medicaid

⁽a) Includes \$ 6,617,956 premium deficiency reserve.

PART 3 - ANALYSIS OF EXPENSES

	FARI 3 - AIV	NALYSIS OF EXPE		1	1	1
		Claim Adjustn	•	3	4	5
		1	2			
		Cost	Other Claim	General		
		Containment	Adjustment	Administrative	Investment	
		Expenses	Expenses	Expenses	Expenses	Total
1.	Rent (\$ for occupancy of own building)					
2.	Salaries, wages and other benefits					
3.	Commissions (less \$ ceded plus \$ assumed)			2,286,446		2,286,446
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses					
8.	Marketing and advertising					
9.	Postage, express and telephone	12,492	1,922	81,676		96,090
10.	Printing and office supplies.	9,469	1,457	61,910		72,835
11.	Occupancy, depreciation and amortization	– .				
12.	Equipment					
13.	Cost or depreciation of EDP equipment and software					
14.	Outsourced services including EDP, claims, and other services	624,460	680,484	3,066,460		4,371,403
15.	Boards, bureaus and association fees.	–	–			
16.	Insurance, except on real estate	–	–			
17.	Collection and bank service charges	–	–		26,010	26,010
18.	Group service and administration fees	–	–			
19.	Reimbursements by uninsured plans	–	-	_		
20.	Reimbursements from fiscal intermediaries	–	–			
21.	Real estate expenses	–	–			
22.	Real estate taxes	—				
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	—	–			
	23.2 State premium taxes	—	–	9,354		9,354
	23.3 Regulatory authority licenses and fees			23,881		23,881
	23.4 Payroll taxes		–	–		
	23.5 Other (excluding federal income and real estate taxes)			11,880		11,880
24.	Investment expenses not included elsewhere		–	–	–	
25.	Aggregate write-ins for expenses					
26.	Total expenses incurred (Lines 1 to 25)	1,061,600	747,735	9,421,558	26,010	(a) 11,256,902
27.	Less expenses unpaid December 31, current year		418,075	2,700		420,775
28.	Add expenses unpaid December 31, prior year		280,829	90,322		371,151
29.	Amounts receivable relating to uninsured plans, prior year					
30.	Amounts receivable relating to uninsured plans, current year					
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30).	1,061,600	610,488	9,509,180	26,010	
	ils of Write-Ins	.,,,,,,,,		2,002,100	20,010	,
2501						
2502)					
2503						
2598	B. Summary of remaining write-ins for Line 25 from overflow page					
	9. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)					

⁽a) Includes management fees of \$ 8,363,175 to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. Government bonds	(a)	28,467
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated).	(a)	
1.3	Bonds of affiliates.		
2.1	Preferred stocks (unaffiliated)	(b)	
2.11	Preferred stocks of affiliates	(b)	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans	(c)	
4.	Real estate	(d)	
5.	Contract loans		
6.	Cash, cash equivalents and short-term investments.	(e)	4,774
7.	Derivative instruments.	(f)	
8.	Other invested assets		
9.	Aggregate write-ins for investment income		
10.	Total gross investment income	28,015	
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		
Detai	ls of Write-Ins		
0901.			
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page		
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)		
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15 above)		

- (a) Includes \$ 4,281 accrual of discount less \$ 4,308 amortization of premium and less \$ 1,999 paid for accrued interest on purchases.

- (a) Includes \$ 4,281 accrual of discount less \$ 4,308 amortization of premium and less \$ 1,999 paid for accrued interest on purchases.

 (b) Includes \$ accrual of discount less \$ amortization of premium and less \$ paid for accrued dividends on purchases.

 (c) Includes \$ accrual of discount less \$ amortization of premium and less \$ paid for accrued interest on purchases.

 (d) Includes \$ for company's occupancy of its own buildings; and excludes \$ interest on encumbrances.

 (e) Includes \$ 4,628 accrual of discount less \$ amortization of premium and less \$ paid for accrued interest on purchases.

 (f) Includes \$ accrual of discount less \$ amortization of premium.

 (g) Includes \$ investment expenses and \$ investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.

 (h) Includes \$ depreciation on real estate and \$ depreciation

EXHIBIT OF CAPITAL GAINS (LOSSES)

		EXHIBIT OF C	APITAL GAINS	(LUSSES)		
		1	2	3	4	5
		Realized Gain (Loss) On Sales or Maturity	Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1.	U.S. Government bonds	(77,107)		(77,107)		
1.1	Bonds exempt from U.S. tax					
1.2	Other bonds (unaffiliated)					
1.3	Bonds of affiliates					
2.1	Preferred stocks (unaffiliated)					
2.11	Preferred stocks of affiliates					
2.2	Common stocks (unaffiliated)					
2.21	Common stocks of affiliates					
3.	Mortgage loans					
4.	Real estate					
5.	Contract loans					
6.	Cash, cash equivalents and short-term investments					
7.	Derivative instruments					
8.	Other invested assets				1,514,691	
9.	Aggregate write-ins for capital gains (losses)					
10.	Total capital gains (losses)	(77,107)		(77,107)	1,514,691	
Detail	s of Write-Ins					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page					
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)					

EXHIBIT OF NONADMITTED ASSETS

	EXHIBIT OF N	IONADMITTED ASSI		2
		1	2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 – Col. 1)
1.	Bonds (Schedule D)	140Hddffiltted 7100eto	140maammaca 7 toocto	(001. 2 001. 1)
2.	Stocks (Schedule D):			
	2.1 Preferred stocks			
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens			
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company			
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
5.	Cash (Schedule E-Part 1), cash equivalents (Schedule E-Part 2)			
	and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	56,230		(56,230)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
17.	Amounts receivable relating to uninsured plans		2,465	
18.1	Current federal and foreign income tax recoverable and interest			
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange			
00	rates			
23.	Receivables from parent, subsidiaries and affiliates			, , ,
24.	Health care and other amounts receivable.	•	•	, , ,
25. 26.	Aggregate write-ins for other-than-invested assets Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			,
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts.			(039,993)
20	Total (Lines 26 and 27)		205 671	(620,002)
28.		1,035,664	395,671	(639,993)
	ils of Write-Ins			
_				
	Summary of remaining write-ins for Line 11 from overflow page.			
	. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)			
	. Miscellaneous Receivables			, ,
	Commence of commission with in a fact time 25 from a conflavor			
	Summary of remaining write-ins for Line 25 from overflow page.			
∠599	. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	1,196 .		(1,196)

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		T	otal Members at End o	f		6
	1	2	3	4	5	
Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Current Year Membe Months
1. Health Maintenance Organizations	5,491	6,041	6,169	6,286	6,298	74,119
2. Provider Service Organizations						
3. Preferred Provider Organizations						
4. Point of Service						
5. Indemnity Only						
5. Aggregate write-ins for other lines of business						
7. Total	5,491	6,041	6,169	6,286	6,298	74,119
Details of Write-Ins						
0601						
0602						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page						
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)						

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Clover HMO of New Jersey, Inc. (the "Company") have been prepared in conformity with accounting practices prescribed or permitted by the state of New Jersey for determining and reporting the financial conditions and results of operations of an insurance company for determining its solvency under New Jersey Code. The National Association of Insurance Commissioners ("NAIC") Accounting Practices and Procedures Manual, ("NAIC SAP") has been adopted as a component of prescribed or permitted practices by the State of New Jersey Department of Banking and Insurance (DOBI).

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the state of New Jersey is shown below:

	SSAP#	F/S Page	F/S Line #	 2021	 2020
Net Income					
(1) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (17,767,214).	\$ (433,994).
(2) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(3) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ (17,767,214)	\$ (433,994)
Surplus					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 15,373,683 .	\$ 11,216,199 .
(6) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(7) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 15,373,683	\$ 11,216,199

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

C. Accounting Policy

Health capitation premiums are recognized in the period members are entitled to related health care services. Health care service costs and the related liabilities for claims payable are recorded when medical services are authorized, as well as when services are provided without authorization to the extent such services are expected to be ultimately authorized. Expenses are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments are stated at amortized cost.
- (2) Bonds are stated at amortized cost using the scientific interest method. The Company does not own any mandatory convertible securities or SVO-Identified bond ETFs.
- (3) The Company had no investments in common stock.
- (4) The Company had no investments in preferred stock.
- (5) The Company had no investments mortgage loans.
- (6) The Company has no loan-backed securities.
- (7) The Company carries its 100% owned subsidiary, MSPNJ, LLC on an audited GAAP equity basis in accordance with SSAP No. 97; 8b.III.
- (8) The Company had no investments in joint ventures or partnerships. The Company carries investments in limited liability companies on an audited GAAP equity basis in accordance with SSAP No. 97; 8b.III.
- (9) The Company had no investments in derivative instruments.
- (10) The Company utilizes anticipated investment income as a factor in the premium deficiency calculation.
- (11) Unpaid losses and loss adjustment expenses include amounts determined from claims estimates and loss reports and an amount, based on past experience, for losses incurred but not reported. Such liabilities are necessarily based on assumptions and estimates and while management believes the amount is adequate, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liability are continually reviewed and any adjustments are reflected in the period determined.
- (12) The Company's capitalization policy has not changed.
- (13) The Company's pharmaceutical rebate receivables are based on actual billed rebates. Any rebates billed and unpaid after 90 days are non-admitted.

D. Going Concern

Management has evaluated the Company's ability to continue as a going concern. In Management's assessment there is no substantial doubt in the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors - None

3. Business Combinations and Goodwill

A. Statutory Purchase Method - None

3. Business Combinations and Goodwill (Continued)

- B. Statutory Merger None
- C. Assumption Reinsurance None
- D. Impairment Loss None
- E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill None

4. Discontinued Operations

- A. Discontinued Operation Disposed of or Classified as Held for Sale None
- B. Change in Plan of Sale of Discontinued Operation None
- C. Nature of Any Significant Continuing Involvement with Discontinued Operations After Disposal None
- D. Equity Interest Retained in the Discontinued Operation After Disposal None

Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans None
- B. Debt Restructuring None
- C. Reverse Mortgages None
- D. Loan-Backed Securities None
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions None
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing None
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing None
- H. Repurchase Agreements Transactions Accounted for as a Sale None
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale None
- J. Real Estate None
- K. Low-Income Housing Tax Credits (LIHTC) None
- L. Restricted Assets
 - (1) Restricted assets (including pledged)

Nonadmited) Nonadmited) Total Current Total Current Nonadmitted) Restricted Restricted Increase / Year Year Admitted Restricted to Total			(1)		(2)	(3)	(4)	(5)	(6)	(7)
b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar reverse repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)		Restricted Asset Category	(Admitte Nonadmi Restricte from Curr	d & ted) ed rent	(Admitted & Nonadmited) Restricted From Prior	(Decrease)	Year Nonadmitted	Year Admitted Restricted	(Admitted & Nonadmitted Restricted to Total	l)Restricted to Total Admitted
c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)	a.	Subject to contractual obligation for which liability is not shown	\$		\$	\$	\$	\$	%.	%.
d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)	b.	Collateral held under security lending agreements								
e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)	C.	Subject to repurchase agreements								
f. Subject to dollar reverse repurchase agreements. g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock. i. FHLB capital stock. j. On deposit with states. 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies. l. Pledged as collateral to FHLB (including assets backing funding agreements)	d.	Subject to reverse repurchase agreements								
g. Placed under option contracts h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states	e.	Subject to dollar repurchase agreements								
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)	f.	Subject to dollar reverse repurchase agreements								
i. FHLB capital stock j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies l. Pledged as collateral to FHLB (including assets backing funding agreements)	g.	Placed under option contracts								
j. On deposit with states 8,331,720 1,264,623 7,067,097 - 8,331,720 22.791 23.455 k. On deposit with other regulatory bodies 8,391,720 20.791 23.455 l. Pledged as collateral to FHLB (including assets backing funding agreements)	h.	Letter stock or securities restricted as to sale - excluding FHLB capital stock								
k. On deposit with other regulatory bodies	i.	FHLB capital stock								
I. Pledged as collateral to FHLB (including assets backing funding agreements)	j.	On deposit with states	8,331	,720	1,264,623	7,067,097		8,331,720	22.791	23.455
	k.	On deposit with other regulatory bodies								
m. Pledged as collateral not captured in other categories	I.	Pledged as collateral to FHLB (including assets backing funding agreements)								
	m	. Pledged as collateral not captured in other categories								
n. Other restricted assets	n.	Other restricted assets								
o. Total restricted assets \$ 8,331,720 \$ 1,264,623 \$ 7,067,097 \$ - \$ 8,331,720 22.791 % 23.455	0.	Total restricted assets	\$ 8,331	,720	\$ 1,264,623	\$ 7,067,097	\$ -	\$ 8,331,720	22.791 %	23.455 %

- (2) Detail of assets pledged as collateral not captured in other categories (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate) None
- (3) Detail of other restricted assets (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate) None
- (4) Collateral received and reflected as assets within the reporting entity's financial statements None
- M. Working Capital Finance Investments None
- N. Offsetting and Netting of Assets and Liabilities None
- O. 5GI Securities None
- P. Short Sales None
- Q. Prepayment Penalty and Acceleration Fees None
- R. Reporting Entity's Share of Cash Pool by Asset type None

6. Joint Ventures, Partnerships and Limited Liability Companies

- A. Investments in Joint Ventures, Partnerships or Limited Liability Companies that Exceed 10% of Admitted Assets None
- B. Impaired Investments in Joint Ventures, Partnerships and Limited Liability Companies None

7. Investment Income

- A. Due and Accrued Income Excluded from Surplus None
- B. Total Amount Excluded None

8. Derivative Instruments

- A. Derivatives under SSAP No. 86 Derivatives None
- B. Derivatives under SSAP No. 108 Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) None

9. Income Taxes

A. Components of the Net Deferred Tax Asset/(Liability)

The statutory basis of accounting requires that the Company record deferred tax assets and liabilities for certain temporary differences between statutory basis income before federal income taxes, plus certain items recorded directly to surplus, and taxable income as reflected in the Company's federal income tax return, subject to certain limitations.

(1) Change between years by tax character

			2021			2020			Change	
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
		Ordinary	Capital	Total (Col 1+2)	Ordinary	Capital	Total (Col 4+5)	Ordinary (Col 1-4)	Capital (Col 2-5)	Total (Col 7+8)
(a)	Gross deferred tax assets	\$ 4,763,358 .	\$ 590,139 .	\$ 5,353,496	\$ 1,257,879	\$	\$ 1,257,879	\$ 3,505,479	\$ 590,139	\$ 4,095,618 .
(b)	Statutory valuation allowance adjustments	4,712,622	590,139	5,302,761	1,224,538		1,224,538	3,488,084	590,139	4,078,222
(c)	Adjusted gross deferred tax assets (1a - 1b)	50,735 .		50,735	33,340 .		33,340	17,395	–	17,395
(d)	Deferred tax assets nonadmitted									
(e)	Subtotal net admitted deferred tax asset (1c - 1d)	\$ 50,735 .	\$	\$ 50,735	\$	\$	\$ 33,340	\$ 17,395	\$	\$ 17,395
(f)	Deferred tax liabilities	50,735 .		50,735	33,340		33,340	17,395		17,395 .
(g)	Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$ -	\$ -	\$ -	\$ -	\$	\$	\$ -	\$ -	\$ -

(2) Admission calculation components SSAP No. 101

		2021			2020			Change	
	(1)	(2)	(3) Total (Col 1+2)	(4) Ordinary	(5)	(6) Total (Col 4+5)	(7) Ordinary	(8) Capital	(9) Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	Ordinary \$	Capital			Capital		(Col 1-4)	(Col 2-5)	(Col 7+8)
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation (lesser of 2(b)1 and 2(b)2 below)									
Adjusted gross deferred tax assets expected to be realized following the balance sheet date				33,340		33,340)(33,340)		(33,340
Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	2,306,052	XXX	XXX		XXX	XXX	2,306,05
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities	50,735		50,735				50,735		50,73
d) Deferred tax assets admitted as the result of application of SSAP No. 101.							_		
Total (2(a) + 2(b) + 2(c))	\$ 50,735	\$	\$ 50,735	\$	\$	\$	\$ 50,735	\$	\$ 50,73

(3) Ratio used as basis of admissibility

	2021	2020
(a) Ratio percentage used to determine recovery period and threshold limitation amount	415.800 %.	445.125 %.
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2(b)2 above	\$ 15,373,683	\$ 11,216,199

9. Income Taxes (Continued)

- (4) Impact of tax-planning strategies
 - (a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage

				20	21		2020			Change	
			_	(1)	(2)		(3)	(4)	(5)		(6)
				Ordinary	Capital		Ordinary	Capital	Ordinar (Col. 1-3	·.	Capital (Col. 2-4)
			 1. Adjusted gross DTAs amount from Note 9A1(c)\$. – Ś			<u>`</u>	<u> </u>	, ,
			Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies								
		;	3. Net admitted adjusted gross DTAs amount from Note 9A1(e) \$								
			 Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies 								
	(b)) U	se of reinsurance-related tax-planning strategies								
		D	oes the company's tax-planning strategies include	e the use of re	einsurance?						NO
B.	Regard	ling	Deferred Tax Liabilities That Are Not Recognized	- None							
C.	Maior (Con	nponents of Current Income Taxes Incurred								
О.	wajor	0011	ponente of ouncil moonie raxes mounted								
								(1)	(2)		(3)
			come taxes incurred consist of the following major o ent Income Tax	components:				2021	2020		Change (1-2)
			Federal						. \$	\$.	
		•	Foreign								
	(0	c)	Subtotal				\$		\$	\$.	
	(0	d)	Federal income tax on net capital gains								
	(6	e)	Utilization of capital loss carry-forwards								
	(f	,	Other								
	(9	g)	Federal and foreign income taxes incurred				<u>\$</u>		\$	\$	
								(1) 2021	(2) 2020		(3) Change (1-2)
	2. D	efe	rred Tax Assets						-		3 ()
	(a	a)	Ordinary								
			(1) Discounting of unpaid losses				\$	33,456	\$ 24,9	78 \$.	8,478
			(2) Unearned premium reserve								
			(3) Policyholder reserves					1,389,771	226,8	00	1,162,971
			(4) Investments								
			(5) Deferred acquisition costs								
			(6) Policyholder dividends accrual								
			(7) Fixed assets								
			(8) Compensation and benefits accrual(9) Pension accrual								
			(10) Receivables - nonadmitted								
			(11) Net operating loss carry-forward								
			(12) Tax credit carry-forward						•		
			(13) Other (including items less than 5% of total ord								
			(99) Subtotal				\$	4,763,358	\$ 1,257,8	79 \$.	3,505,479
	(b	b)	Statutory valuation allowance adjustment					4,712,622	1,224,5	38	3,488,084
	(0	,	Nonadmitted								
			Admitted ordinary deferred tax assets (2a99 - 2b - 2c)			\$	50,735	\$ 33,3	40 . \$.	17,395
	(€	•	Capital (1) Investments				ė	572 240	ė	ć	572 240
			(1) Investments					-			·
			(3) Real estate								·
			(4) Other (including items <5% of total capital tax a								
			(99) Subtotal								
	(f	f)	Statutory valuation allowance adjustment								
	(9	g)	Nonadmitted								
	(h	h)	Admitted capital deferred tax assets (2e99 - 2f - 2g)								–
	(i	i)	Admitted deferred tax assets (2d + 2h)				\$	50,735	\$ 33,3	40 \$	17,395

9. Income Taxes (Continued)

				(1) 2021		(2) 2020	Cha	(3) inge (1-2)
3.	Def	erred	Tax Liabilities					
	(a)	Ordi	inary					
		(1)	Investments	\$		\$	\$	
		(2)	Fixed assets					
		(3)	Deferred and uncollected premium					
		(4)	Policyholder reserves					
		(5)	Other (including items <5% of total ordinary tax liabilities) [†]	50,7	735	33,340		17,395
			(99) Subtotal					
	(b)	Сар	ital					
		(1)	Investments	\$		\$	\$	
		(2)	Real estate					
		(3)	Other (including items <5% of total capital tax liabilities)					
			(99) Subtotal	\$		\$	\$	
	(c)	Defe	erred tax liabilities (3a99 + 3b99)	\$ 50,7	735	\$ 33,340	\$	17,395
4.	Net	defe	rred tax assets/liabilities (2i - 3c)	\$	_	\$ -	\$	
				(1)		(2)		(3)
				2021		2020	Cha	inge (1-2)
† I	tems	>5%	of total ordinary tax liabilities included in Other					
(ood,	will		\$ 50.7	735	\$ 33,340	Ś	17 395

The change in net deferred income taxes is comprised of the following, before consideration of non-admitted deferred tax assets:

-	12/31/2021	12/30/2020	Change
Adjusted gross deferred tax assets	50,735	33,340	(17,395)
Total deferred tax liabilities	50,735	33,340	(17,395)
Net deferred tax assets (liabilities)	0	0	(0)
Tax effect of change in unrealized gair	ns (losses)		-
Total change in net deferred income to			(0)

D. Among the More Significant Book to Tax Adjustments

The provision for federal income taxes incurred is different from that which would be obtained by applying the federal income tax rate to statutory income before income taxes. The items causing this difference are as follows:

	 2021	Effective Tax Rate
Provision computed at statutory rate	\$ (3,731,115)	21.000 %
Permanent Differences	 	
Prior Year True Up (to Deferred)	 	
Change in Non-admitted Assets	 (134,399)	0.756
Change in deferred income taxes	 	
Income in Equity of Subsidaries	 	
Change in Valuation Allowance	 3,865,513	21.756
Total	\$ 	- %
	 2021	
Federal and foreign income taxes incurred	\$ 	
Current taxes on realized capital gains	 	
Total statutory income taxes	\$ 	%
	 2020	
Provision computed at statutory rate	\$ (91,139)	-21.000 %
Permanent Differences	89 813	20.695
Prior Year True Up (to Deferred)		
Prior Year True Up (to Deferred) Change in Non-admitted Assets	 (1,587)	-0.366
	 (1,587)	-0.366
Change in Non-admitted Assets	 (1,587)	-0.366
Change in Non-admitted Assets Change in deferred income taxes Income in Equity of Subsidaries Change in Valuation Allowance	310,196	71.475
Change in Non-admitted Assets Change in deferred income taxes Income in Equity of Subsidaries	310,196	71.475
Change in Non-admitted Assets Change in deferred income taxes Income in Equity of Subsidaries Change in Valuation Allowance	310,196	-0.366 -71.475 -70.804 - %
Change in Non-admitted Assets Change in deferred income taxes Income in Equity of Subsidaries Change in Valuation Allowance	\$ 310,196 (307,284)	-0.366
Change in Non-admitted Assets Change in deferred income taxes Income in Equity of Subsidaries Change in Valuation Allowance Total	\$ 310,196 (307,284) ————————————————————————————————————	

9. Income Taxes (Continued)

- E. Operating Loss and Tax Credit Carryforwards
 - At December 31, 2021, the Company had unused operating loss carryforwards available to offset against future taxable income of \$22,682,655.
 The carryforwards begin to expire in 2030.
 - (2) Income tax expense available for recoupment None
 - (3) Deposits admitted under IRS Code Section 6603 None
- F. Consolidated Federal Income Tax Return
 - (1) The Company's federal income tax return is filed on a consolidated basis with:

Clover Health Investments, Corp.

Clover Insurance Company

Clover Health, Corp.

Clover Health Holdings, Inc.

G. Federal or Foreign Income Tax Loss Contingencies

The Company has no tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

The Consolidated Federal Income Tax Returns filed in relation to tax years subsequent to 2017 remain subject to examination by the IRS. The Company is not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. The Company does not have material uncertain tax positions reflected in the statements of admitted assets, liabilities, capital and surplus.

- H. Repatriation Transition Tax (RTT) None
- I. Alternative Minimum Tax (AMT) Credit None

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. The Company along with its affiliated companies have common ownership under Clover Health Investments, Corp. as members of an Holding Company Group.
- B. In February 2021, the Company received the \$1,500,000 surplus contribution approved and recognized as of December 31, 2020 as a receivable from Clover Health Investments, Corp.

In March 2021, the Company received a surplus contribution of \$2,350,000 from Clover Health Investments, Corp. on March 28, 2021.

In April 2021, the Company received the \$3,200,000 surplus contribution approved and recognized as of March 31, 2021 as a receivable from Clover Health Investments, Corp. The funds were received on April 28, 2021.

In June 2021, the Company received a surplus contribution of \$6,000,000 from Clover Health Investments, Corp. The funds were received on June 29, 2021.

In September 2021, the Company received surplus contributions totaling \$5,400,000 from Clover Health Investments, Corp. The contribution dates and amounts received were \$5,000,000 on September 23, 2021 and \$400,000 on September 30, 2021.

In December 2021, the Company received a surplus contribution of \$4,100,000 from Clover Health Investments, Corp. The funds were received on December 28, 2021.

- C. Transactions With Related Party Who Are Not Reported on Schedule Y None
- D. Amounts Due From or Due To Related Parties

The following amounts are due from/(to) the following entities:

Due from Related Parties:	12/31/2021		1	2/31/2020
Clover Health Investments Corp.	\$	579	\$	1,500,000
Clover Insurance Company		37,141		
Total Due from	\$	37,141	\$	1,500,000
Due to Related Parties:	1	2/31/2021	1	2/31/2020
Clover Health, LLC	\$	617,055	\$	116,640
Clover Health Labs, LLC				25,186
Clover Insurance Company		17.0		33,419
MSPNJ, LLC	\$	1,210,866		2,700
Total Due to	\$	1,827,921	\$	177,945
	\$		\$	

E. Material Management Contracts

The Company has an administrative services agreement with Clover Health, LLC (ASO) to make use of certain employees, vendor arrangements and other miscellaneous overhead of the Company. Under the terms of this agreement, which was approved by NJ DOBI, the Company will pay an administrative fee of based on a percentage of the premiums earned for all the services and expenses incurred by ASO on the Company's behalf.

- F. Guarantees or Contingencies None
- G. Common Control The Company is owned by Clover Health Holdings, Inc. which is a member of Clover Health Investments, Corp., a Delaware domesticated company.
- H. Amount Deducted for Investment in Upstream Company None
- I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets None
- J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies None

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties (Continued)

- K. Foreign Subsidiary Value Using CARVM None
- L. Downstream Holding Company Value Using Look-Through Method None
- M. All SCA Investments None
- N. Investment in Insurance SCAs None
- O. SCA and SSAP No. 48 Entity Loss Tracking None

11. Debt

- A. Debt, Including Capital Notes None
- B. FHLB (Federal Home Loan Bank) Agreements None

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A. Defined Benefit Plan None
- B. Investment Policies and Strategies of Plan Assets None
- C. Fair Value of Each Class of Plan Assets None
- D. Expected Long-Term Rate of Return for the Plan Assets None
- E. Defined Contribution Plans None
- F. Multiemployer Plans None
- G. Consolidated/Holding Company Plans None
- H. Postemployment Benefits and Compensated Absences None
- I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17) None

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. On April 2018, Clover Health Investments, Corp. purchased \$10 of common stock of the Company for capital funding. The Company has 1,000 shares at \$1 per share authorized and outstanding and has only issued 10 shares.
- B. Dividend Rate of Preferred Stock None
- C. The Company's ability to declare and pay dividends is limited by state regulations. Also such regulations do not specifically restrict the Company from paying dividends; rather they require the Company to be financially sound as determined by the NJ Department of Banking and Insurance.
- D. Ordinary Dividends None
- E. Company Profits Paid as Ordinary Dividends None
- F. Surplus Restrictions None
- G. Surplus Advances None
- H. Stock Held for Special Purposes None
- I. Changes in Special Surplus Funds None
- J. Unassigned Funds (Surplus)
 - The portion of unassigned funds represented or reduced by unrealized gains or (losses) is \$2,961,790.
- K. Company-Issued Surplus Debentures or Similar Obligations None
- L. Impact of Any Restatement Due to Prior Quasi-Reorganizations None
- M. Effective Date(s) of Quasi-Reorganizations in the Prior 10 Years None

14. Liabilities, Contingencies and Assessments

- A. Contingent Commitments None
- B. Assessments None
- C. Gain Contingencies None
- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits None
- E. Joint and Several Liabilities None
- F. All Other Contingencies None

15. Leases

- A. Lessee Operating Lease None
- B. Lessor Leases None

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk

- $1. \quad \text{Face Amount of the Company's Financial Instruments with Off-Balance-Sheet Risk-None} \\$
- 2. Nature of Terms None

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk (Continued)

- 3. Exposure to Credit Related Losses None
- 4. Collateral Policy None

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

- A. Transfers of Receivables Reported as Sales None
- B. Transfer and Servicing of Financial Assets None
- C. Wash Sales None

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

- A. ASO Plans None
- B. ASC Plans None
- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract
 - (1) Revenue from the Medicare Part D cost based reimbursement portion of the contract for the year 2021, consisted of \$6,348,483 for reinsurance subsidy and \$4,848,310 for low-income cost sharing subsidy and \$5,441,401 for reinsurance subsidy and \$3,780,354 for low-income cost sharing subsidy for 2020.
 - (2) In connection to the Company's Medicare Part D contract, the Company has recorded an allowance receivable in the amount of \$658,448 for Reinsurance Subsidy as of December 31, 2021.
 - (3) In connection to the Company's Medicare Part D contract, the Company has recorded an allowance payable of \$215,562 for low-income cost sharing subsidy as of December 31, 2021; this payable has been offset against the Reinsurance Subsidy receivable and the net receivable reported on the Assets page. As of December 31, 2020, the Company had an allowance payable in the amount of \$279,675 for Reinsurance Subsidy and \$139,206 for low-income cost sharing subsidy.
 - (4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators - None

20. Fair Value Measurements

- A. Fair Value Measurement
 - (1) Fair value measurements at reporting date

The Company's financial assets and liabilities carried at fair value have been classified, for disclosure purposes, based on a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The hierarchy gives the highest priority to fair values determined using unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to fair values determined using unobservable inputs (Level 3). An asset's or liability's classification is determined based on the lowest level input that is significant to its measurement.

For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The levels of the fair value hierarchy are as follows:

- Level 1: Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
- Level 2: Inputs are other than quoted prices included in level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
- Level 3: Inputs are unobservable and reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

Fair value of actively traded fixed-income and equity securities is based on quoted market prices. Fair value of inactively traded fixed-income securities is based on quoted market prices of identical or similar securities based on observable inputs like interest rates using a market valuation approach is generally classified as Level 2. Investments measured based on the practical expedient being net asset value (NAV), based on the NAV of the fund as provided for in the audited financial statements and other fund reporting, are generally classified as Level 3.

	Description for each class of asset or liability	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total	
a.	Assets at fair value						
	Sweep Accounts	\$	\$ 3,871,673	\$	\$	\$ 3,871,67	73
	Cash Equivalent - Exempt Money Market Mutual Funds		98,086			98,08	86
	Cash Equivalent - Other Money Market Mutual Funds		105,877			105,87	77
	Total assets at fair value/NAV	\$	\$ 4,075,636	\$	\$	\$ 4,075,63	36
b.	Liabilities at fair value						
	Total liabilities at fair value	\$	\$	\$	\$	\$	_

- (2) Fair value measurements in Level 3 of the fair value hierarchy None
- (3) The Company's policy for determining when transfers between levels are recognized is determined at the end of the reporting period.
- (4) Inputs and techniques used for Level 2 and Level 3 fair values None
- (5) Derivatives None
- B. Other Fair Value Disclosures None

20. Fair Value Measurements (Continued)

C. Fair Values for All Financial Instruments by Level 1, 2 and 3

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$ 10,279,259	\$ 10,347,960	\$	\$ 10,279,259	\$	\$	\$
Short-term Investments	3,891,303	3,895,028		3,891,303			
Sweep Accounts	3,871,673	3,871,673		3,871,673			
Cash Equivalents	203,963	203,963		203,963			

- D. Not Practicable to Estimate Fair Value None
- E. Nature and Risk of Investments Reported at NAV None

21. Other Items

- A. Unusual or Infrequent Items None
- B. Troubled Debt Restructuring None
- C. Other Disclosures None
- D. Business Interruption Insurance Recoveries None
- E. State Transferable and Non-Transferable Tax Credits None
- F. Subprime-Mortgage-Related Risk Exposure None
- G. Retained Assets None
- H. Insurance-Linked Securities (ILS) Contracts None
- The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy - None

22. Events Subsequent

Type I. - Subsequent events have been considered through February 28, 2022 for the statutory statement issued on December 31, 2021 - None

Type II. - Subsequent events have been considered through February 28, 2022 for the statutory statement issued onDecember 31, 2021 - None

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes () No (X)

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

- B. Uncollectible Reinsurance None
- C. Commutation of Reinsurance Reflected in Income and Expenses None
- D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation None
- E. Reinsurance Credit
 - (1) Reinsurance contracts subject to A-791 None
 - (2) Reinsurance contracts not subject to A-791

The Company has one reinsurance contract with Partnerre American Insurance Company covering the Medicare business with risk limiting features. The reinsurance credit was reduced for the risk limiting features.

- (3) There are no provisions that delay payment in form or in fact within the contract.
- (4) The reinsurance contract with Partnerre American Insurance Company meets the risk transfer requirements of SSAP No. 61R. This contract is a stop loss contract with a deductible that does not result in significant surplus relief.

23. Reinsurance (Continued)

- (5) Contracts with ceded risk not subject to A-791 accounted for differently under GAAP and SAP None
- (6) Explanation of the accounting treatment disclosed in Note 23.E(5) if treated differently for GAAP and SAP None

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate

The Company estimates accrued retrospective premium adjustments for its Medicare Part D based on the Company's underwriting rules and experience rating practices.

B. Method Used to Record

The Company records accrued retrospective premium as an adjustment to earned premium.

C. Amount and Percent of Net Retrospective Premiums

The amount of net premiums written by the Company in 2021 that are subject to retrospective rating features is \$4,209,628 representing 5.7% of the total net premiums written. For 2020, these amounts were \$3,481,613 representing 6.5% of the total net premiums written in that year.

- D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act None
- E. Risk-Sharing Provisions of the Affordable Care Act (ACA)
 - (1) Accident and health insurance premium subject to the Affordable Care Act risk-sharing provisions

Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions? NO

- (2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year None
- (3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance None
- (4) Roll-forward of risk corridors asset and liability balances by program benefit year None
- (5) ACA risk corridors receivable as of reporting date None

25. Change in Incurred Claims and Claim Adjustment Expenses

A. Reasons for Changes in the Provision for Incurred Claim and Claim Adjustment Expenses Attributable to Insured Events of Prior Years

Reserves as of December 31, 2020 were \$7,842,767. As of December 31, 2021 \$9,674,741 has been paid for incurred claims and claims adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$465,298 as a result of re-estimation of unpaid claims and claims adjustment expenses; therefore, there has been \$2,297,272 in unfavorable prior-year development from December 31, 2020 to December 31, 2021. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

B. Significant Changes in Methodologies and Assumptions Used in Calculating the Liability for Unpaid Claims and Claim Adjustment Expenses - None

26. Intercompany Pooling Arrangements - None

27. Structured Settlements - None

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2021	\$ 2,315,294	\$ 2,315,294	\$	\$	\$
09/30/2021	2,077,878 .	2,077,878	1,895,790		
06/30/2021	2,297,672 .	2,297,672	1,884,120		
03/31/2021	1,752,461 .	1,752,461	1,773,435	119,338	(112,295)
12/31/2020	2,036,199 .	2,036,199	777,143	233,290	110,497
09/30/2020		1,579,420	1,470,957	568,379	64,022
06/30/2020	1,433,525 .	1,433,525	1,231,049		
03/31/2020			1,065,161	262,511	200,998
12/31/2019	838,826	838,826	702,084	66,033	26,496
09/30/2019		758,458	701,773	114,761	8,807
06/30/2019	616,520 .	616,520	508,965	–	47,446
03/31/2019	528,359 .	528,359	430,015		

B. Risk-Sharing Receivables - None

29. Participating Policies - None

30. Premium Deficiency Reserves

Investment income was considered, however, presumed income from investments would be zero given the unpredictability of external factors associated with investment performance in future periods.

30. Premium Deficiency Reserves (Continued)

Liability carried for premium deficiency reserves: \$6,617,956
 Date of the most recent evaluation of this liability: 12/31/2021
 Was anticipated investment income utilized in the calculation? YES

31. Anticipated Salvage and Subrogation - None

GENERAL

1.1.			rance Holding Company System con					VEQ
	If yes, complete Schedule Y, Parts						•••••	1 L3
1.2.	If yes, did the reporting entity reg regulatory official of the state of disclosure substantially similar to Insurance Holding Company Sys	ister and f domicile o o the stan tem Regu	file with its domiciliary State Insurand of the principal insurer in the Holding Idards adopted by the National Assoc latory Act and model regulations per	Company System ciation of Insurand taining thereto, or	n, a regis ce Comn is the re	stration statement missioners (NAIC) porting entity sub	providing in its Model ject to	VEC
13			bstantially similar to those required b	-	-			
1.4.			nember of a publicly traded group?					
1.5.								
2.1.	Has any change been made durir	ng the yea	ar of this statement in the charter, by-	aws, articles of in	corpora	tion, or deed of se	ttlement of	
2.2.	, ,							
3.1. 3.2.	 State as of what date the latest financial examination of the reporting entity was made or is being made. State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 							
3.3.	domicile or the reporting entity. T	his is the	xamination report became available release date or completion date of th	e examination rep	oort and	not the date of th	e examination	10/28/2021
3.4.	By what department or departme							10/ 20/ 2021
	The New Jersey Department of B		nd Insurance					
3.5.	• •	•	within the latest financial examinatio	n renort been acco	ounted f	or in a subsequen	t financial	
5.5.								YES
3.6.			e latest financial examination report					
4.1.	·							
4.0								NO
4.2.	affiliate, receive credit or commis direct premiums) of:	sions for	nt, did any sales/service organization or control a substantial part (more th	an 20 percent of a	any maj	or line of business	measured on	
- 1			P.L.e. I. S. d.					
5.1.	If yes, complete and file the merg		nerger or consolidation during the pe	riod covered by th	ıs stater	ment?		NO
5.2.		ntity, NAIĆ	company code, and state of domicile	e (use two letter st	tate abb	reviation) for any	entity that has	
			1	2		3	7	
			Name of Entity	NAIC Company (Code	State of Domicile		
			Name of Littly	TVAIC COmpany (code (State of Domicie	+	
6 1	Has the reporting entity had any	Cortificate	es of Authority, licenses or registration	as (including corn	oroto ro	giotration if applie		
0.1.			al entity during the reporting period?					NO
6.2.			3 - 1 - 3 - 1 - 3 - 1 - 1					
7.1. 7.2.		ates) perso	on or entity directly or indirectly contr	ol 10% or more of	the repo	orting entity?		NO
			rol					%
			n person(s) or entity(s); or if the entity ope of entity(s) (e.g., individual, corpo					
	-		1	-	2			
			NI=41==124	_				
		<u> </u>	Nationality		ype of E			
8.1.		deposito	ry institution holding company (DIHC) or a DIHC itself,	regulate	ed by the Federal F		NO
8.2.	If response to 8.1 is yes, please in	dentify the	e name of the DIHC					
8.3.			banks, thrifts or securities firms?					NO
8.4.	federal financial regulatory service	ces agenc	e names and locations (city and state y [i.e. the Federal Reserve Board (FRE IIC) and the Securities Exchange Com	3), the Office of the	e Compt	roller of the Curre	ncy (OCC), the	
	1		2		3	4	5	6
	Affiliate Name		Location (City, State)		FRB	occ	FDIC	SEC
	. unitate radific		Location (orly, otate)				. 510	J_0
			•					

		itory institution holding company with significant System or a subsidiary of the reporting entity?			NO	
8.6.	If response to 8.5 is no, is the	reporting entity a company or subsidiary of a cor al rule?	npany that has otherwise been made subject	to the	NO	
		s of the independent certified public accountant o			10	
	Ernst & Young LLP, 5 Times So	quare, New York, NY 10036-6530	•			
	accountant requirements as a	any exemptions to the prohibited non-audit service Illowed in Section 7H of the Annual Financial Rep	orting Model Regulation (Model Audit Rule),	or	NO	
		ror regulation? provide information related to this exemption:			NU	
	allowed for in Section 18A of	any exemptions related to the other requirements the Model Regulation, or substantially similar sta			NO	
10.4.	If the response to 10.3 is yes,	provide information related to this exemption:				
	0.5. Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws?					
		d affiliation (officer/employee of the reporting en		actuarial		
		ual providing the statement of actuarial opinion/ v, Society of Actuaries Member, American Acaden		Blvd, Ste 150,		
		any securities of a real estate holding company Iding company	or otherwise hold real estate indirectly?	Λ	V O	
		olved				
122	12.13 Total book / adjusted of If yes, provide explanation	earrying value		\$		
12.2.	ii yee, provide explanation					
13.	FOR UNITED STATES BRANC	HES OF ALIEN REPORTING ENTITIES ONLY:				
		de during the year in the United States manager o				
		all business transacted for the reporting entity the				
		s made to any of the trust indentures during the y s the domiciliary or entry state approved the chan				
	Are the senior officers (princip	pal executive officer, principal financial officer, pri	ncipal accounting officer or controller, or pers	ons		
	a. Honest and ethical con	of the reporting entity subject to a code of ethic duct, including the ethical handling of actual or a			'ES	
	professional relationsh	ips; ly and understandable disclosure in the periodic	reports required to be filed by the reporting en	tity:		
		cable governmental laws, rules and regulations;	reports required to be med by the reporting er	tity,		
		porting of violations to an appropriate person or p	ersons identified in the code; and			
1111	e. Accountability for adhe					
14.11	. If the response to 14.1 is no,	please explain:				
1/10	Has the code of othics for as	nior managers been amended?		v	/EC	
		provide information related to amendment(s).		I	E3	
	The Code of Ethics was reiss	ued separately from the General Code of Conduc	t and was amended to be more in line with ex	pectations at		
1/2	a public company level.	ode of ethics been waived for any of the specified	officers?		NO	
		provide the nature of any waiver(s).	i dilicers:		NO	
	,	, , ,				
15.1.		eficiary of a Letter of Credit that is unrelated to re				
15 2		indicate the American Bankers Association (ABA			VO	
13.2.		of Credit and describe the circumstances in which		lg oi		
	1	2	3	4	7	
	American Bankers			1		
	Association (ABA) Routing	Incluing an Openfamilian Book Name	Circumstances That Can Trigger the Letter	A		
	Number	Issuing or Confirming Bank Name	of Credit	Amount \$	_	
		BOARD OF DIRECT		•		
		nvestments of the reporting entity passed upon e	ither by the board of directors or a subordina		′ES	
17.	Does the reporting entity keep thereof?	a complete permanent record of the proceedings	of its board of directors and all subordinate	committees Y		
		tablished procedure for disclosure to its board of				
		rs, directors, trustees or responsible employees th			'ES	

FINANCIAL

19.	Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Genera Accounting Principles)?	
20.1.	Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):	INO
	20.11 To directors or other officers.	\$
	20.12 To stockholders not officers	\$
	20.13 Trustees, supreme or grand (Fraternal only)	\$
20.2.	Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):	A
	20.21 To directors or other officers 20.22 To stockholders not officers	
	20.23 Trustees, supreme or grand (Fraternal only)	
21.1.	Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the li	
	obligation being reported in the statement?	
21.2.	If yes, state the amount thereof at December 31 of the current year:	
	21.21 Rented from others	
	21.22 Borrowed from others	
	21.24 Other	
22.1.	Does this statement include payments for assessments as described in the <i>Annual Statement Instructions</i> other than g	•
	guaranty association assessments?	
22.2.	If answer is yes:	
	22.21 Amount paid as losses or risk adjustment	
	22.22 Amount paid as expenses 22.23 Other amounts paid	•
23 1	Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement?	
	If yes, indicate any amounts receivable from parent included in the Page 2 amount:	
	Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are	
	within 90 days?	NO
24.2.	If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party.	
	1	2
	Is the	e Third-Party
	Age	nt a Related
	Name of Third-Party Par	ty (Yes/No)
	INVESTMENT	
25.01	. Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has control, in the actual possession of the reporting entity on said date? (other than securities lending programs address	
25.02		sed III 20.00)
25.02	For securities lending programs, provide a description of the program including value for collateral and amount of lo	and acquirities
25.03	and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this informatio	
	provided)	
	The Company does not engage in Securities Lending Programs	
25.04	For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined	I in the Risk-
	Based Capital Instructions.	\$
25.05	1 3 7 1 1 3	
25.06	Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the cour outset of the contract?	
25.07		
25.08		
	conduct securities lending?	
25.09	1 3 7 31 3 7	
	25.091. Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2	
	25.092. Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 25.093. Total payable for securities lending reported on the liability page	
26.1.	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not ex	
20.1.	the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option cor	
	currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03)	
26.2.	If yes, state the amount thereof at December 31 of the current year:	
	26.21. Subject to repurchase agreements.	
	26.22. Subject to reverse repurchase agreements 26.23. Subject to dollar repurchase agreements	
	26.24. Subject to donar reputchase agreements	
	26.25. Placed under option agreements.	
	26.26. Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	\$
	26.27. FHLB Capital Stock	\$
	26.28. On deposit with states.	
	26.29. On deposit with other regulatory bodies.	
	Pledged as collateral - excluding collateral pledged to an FHLB	
	26.32. Other	
26.3.	For category (26.26) provide the following:	Ψ
	1 2 3	
	Nature of Restriction Description Amo	unt
		Í

27.2. If yes, has a compre	ehensive description of the	hedging prog	ram been m	nedule DB?ade available to the domici	liary state? If no, atta	ich a d	
27.3. Does the reporting		nedge variable	e annuity gua	arantees subject to fluctuat			
27.4. If the response to 2 27.41 Special accord	7.3 is YES, does the reportion of SSAP N	ng entity utiliz lo. 108	ze:				
27.43 Other account 27.5. By responding YES	ting guidanceto 27.41 regarding utilizing	the special a	ccounting p	rovisions of SSAP No. 108,	the reporting entity a	ittests t	to the
 The reporting Hedging strate Actuarial certe 21 reserves a Financial Offined Hedge company in it 	entity has obtained explicitegy subject to the special affication has been obtained nd provides the impact of the cer Certification has been oping Strategy within VM-21 to actual day-to-day risk mits.	it approval fro accounting pro I which indica the hedging st obtained whice and that the C tigation effort	om the domic ovisions is c ites that the trategy within h indicates t Clearly Define ts.	ciliary state. onsistent with the requirem hedging strategy is incorpo n the Actuarial Guideline Co hat the hedging strategy m ed Hedging Strategy is the	nents of VM-21. Forated within the estable on ditional Tail Expective the definition of the definition of the deging strategy bein	blishm ation A a Clea ng used	ent of VM- Amount. rly I by the
the issuer, converti	ble into equity?			ırrent year mandatorily con			NO
29. Excluding items in entity's offices, vau pursuant to a cust Considerations, F. Handbook?	Schedule E- Part 3 - Specia Ilts or safety deposit boxes odial agreement with a qua Outsourcing of Critical Fund	al Deposits, rea , were all stoc lified bank or ctions, Custoc	al estate, mo ks, bonds ar trust compa lial or Safek	ortgage loans and investme nd other securities, owned the ny in accordance with Sect eeping Agreements of the I	ents held physically in hroughout the current tion 1, III - General Exa NAIC Financial Condit	the re t year h aminat tion Exa	porting neld ion <i>aminers</i> YES
29.01. For agreements the	at comply with the requiren	nents of the N	IAIC Financia	al Condition Examiners Har	ndbook, complete the	follow	ing:
	Name of Custodian(s)				Custodian's Addre	222	
US Bank National Associa	ation		Minneapolis, Minnesota				
29.02. For all agreements location and a con		e requirement	ts of the <i>NAI</i>	C Financial Condition Exan	niners Handbook, pro	vide th	e name,
1	2				3		
Name(s)	Location(s)		Comp	lete Explanation(s)		
29.03. Have there been ar	ny changes, including name	e changes, in t	the custodia	n(s) identified in 29.01 duri	ng the current year?		NO
29.04. If yes, give full and	complete information rela	ting thereto:		3	<u> </u>	4	
Old Custodian	New Cu	ustodian		Date of Change	Reason		
make investment o		eporting entity	y. For assets	managers, broker/dealers, that are managed internall			ting entity, note as such.
	Na	1 me of Firm or	· Individual				2 Affiliation
	ent, LLCef Financial Officer					U A	
29.0597. For those firms designated with 29.0598. For firms/indivitotal assets under the control of the control	/individuals listed in the ta n a "U") manage more than iduals unaffiliated with the der management aggregate	ble for Question 10% of the resting entime to more than	on 29.05, do eporting entit ty (i.e., desig n 50% of the	any firms/individuals unaf ty's invested assets? nated with a "U") listed in t reporting entity's invested a tion code of "A" (affiliated)	he table for Question assets?	29.05,	does the YES YES
table below.	2			3	4		5
Central Registration Depository Number	Name of Firm o			Legal Entity Identifier ((LEI) Registered	d With	Investment Management Agreement (IMA) Filed NO
				Schedule D - Part 2 (diversif Section 5 (b) (1)])?			
30.2. If yes, complete the	following schedule:	- T			T	3	
	1 SIP #		Name of N	2 Mutual Fund	Book/Adj	Carrying Value	
30.2999 TOTAL	الماجعة على المعمل المع		. falld	ah adı da	\$		
30.3. For each mutual fu	nd listed in the table above 1	, complete the		chedule: 2	3 Amount of Mutual Fi Book / Adjusted Cari		4
Name of Mutual Fur	nd (from above table)	Name of Si	gnificant Ho	lding of the Mutual Fund	Value Attributable to Holding	Date of Valuation	

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

for fair value.	ii and long-term bonds and an preferred stoc	cks. Do not substitute amortiz	Led value of Statement value
	1	2	3
	Statement (Admitted) Value	Fair Value	Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
31.1. Bonds	\$	\$14,170,562	\$(72,425)
31.2. Preferred Stocks			
31.3. Totals	\$	\$14,170,562	\$(72,425)
31.4. Describe the sources or methods utilized in determ	nining the fair values:		
Custodian Statement			
32.1. Was the rate used to calculate fair value determin	ed by a broker or custodian for any of the se	ecurities in Schedule D?	YES
32.2. If the answer to 32.1 is yes, does the reporting ent copy) for all brokers or custodians used as a prici			
32.3. If the answer to 32.2 is no, describe the reporting	3		

By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: 34.

Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.

33.1. Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?.....

- b. Issuer or obligor is current on all contracted interest and principal payments.
- The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:

Has the reporting entity self-designated 5GI securities?...

The security was purchased prior to January 1, 2018. a.

fair value for Schedule D:

33.2. If no, list exceptions:

35.

- The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. b.
- The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as an NRSRO which is C. shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
- The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Ч Has the reporting entity self-designated PLGI securities?.

By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-

- designated FE fund:
 - The shares were purchased prior to January 1, 2019.
 - The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. b.
 - The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO C. prior to January 1, 2019.
 - The fund only or predominantly holds bonds in its portfolio. Ч
 - The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
 - The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?.. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2

.NO...

.YES.....

.NO...

NO

- (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:
 - The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.
 - If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.
 - If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the C. transaction for which documentation is available for regulator review.
 - Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.

Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?..

VES

- OTHER
- 38.1. Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?..... 38.2. List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations,

_	service organizations and statistical or fating bureaus during the period covered by this statement.	
	1	2
	Name	Amount Paid
		\$

39.1. Amount of payments for legal expenses, if any?.....

Ś

39.2. List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period

covered by this statement.	
1	2
Name	Amount Paid
	Ś

- 40.1. Amount of payments for expenditures in connection with matters before legislative bodies, officers, or departments of government, if
- 40.2. List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
	\$

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have							
1.2 1.3	If yes, indicate premium earned What portion of Item (1.2) is no							
	Reason for excluding	o () op o () o	on the moundary cappionism.		J. 101.100			···•
						(* 5)		
1.4 1.5	Indicate amount of earned pre- Indicate total incurred claims of							
1.6	Individual policies:	on an ivieur	care Supplement insurance					Ş
1.0	Most current three years:							
	1.61 Total premium earned							\$
	1.62 Total incurred claims							
	1.63 Number of covered lives							
	All years prior to most current to							
	1.64 Total premium earned							
	1.65 Total incurred claims							
1.7	Group policies:							
1.7	Most current three years:							
	1.71 Total premium earned							\$
	1.72 Total incurred claims							
	1.73 Number of covered lives							
	All years prior to most current							
	1.74 Total premium earned							
	1.75 Total incurred claims							
2. He	alth Test:				1 1	2		
					1	2		
					Current Year	Prior Year		
		2.1	Premium Numerator					
		2.2	Premium Denominator					
		2.3	Premium Ratio (2.1/2.2)					
		2.4	Reserve Numerator		\$ 17,899,592	\$ 8,765,321		
		2.5	Reserve Denominator					
	L	2.6	Reserve Ratio (2.4/2.5)		1			
3.1	Has the reporting entity receive returned when, as and if the ea	ed any ender arnings of t	owment or gift from contractin he reporting entity permits?	g hospitals, pl	nysicians, denti	sts, or others th	at is agreed will be	NO
3.2	If yes, give particulars:							
4.1	Have copies of all agreements	stating the	e period and nature of hospitals	s', physicians',	and dentists' c	are offered to s	ubscribers and	
	dependents been filed with the							
4.2	If not previously filed, furnish h							
5.1	Does the reporting entity have	stop-loss r	einsurance?					YES
5.2	If no, explain:							
5.3	Maximum retained risk (see in							
	5.31 Comprehensive Medical.							
	5.32 Medical Only							
	5.36 Other							
6.	Describe arrangement which the							•••
	including hold harmless provis and any other agreements:							
	Provider contracts contain pro-	visions req	uiring providers to hold subscr	ibers harmless	s in the event of	non-payment l	oy insurer.	
7.1	Does the reporting entity set up	p its claim	liability for provider services or	a service dat	e basis?			YES

7.2 If no, give details

GENERAL INTERROGATORIESPART 2 - HEALTH INTERROGATORIES

8.		owing information regarding f providers at start of repor							20.21/
		f providers at start of report							
9.1		ng entity have business su							
9.2	If yes, direct pre	mium earned:							
		with rate guarantees betwe							
		with rate guarantees over 3							
	•	ng entity have Incentive Po	ol, Withhold or	Bonus Arrange	ments in its pro	vider contract	s?		NO
10.2	If yes:	n amount payable bonuses							ė
		ctually paid for year bonus							
		amount payable withhold							
		ctually paid for year withho							
11.1		entity organized as:							
		Group/Staff Model,							
		lual Practice Association (II	•						
11 0		Model (combination of about	,						
		entity subject to Statutory Name of the state requiring							
	•	amount required		•	•				•
		ncluded as part of a contin							
		calculated, show the calcu	• ,		. ,				
		3,666 or 2% of first \$150 m				150 million, or	3 months of u	ncovered expen	ditures, or 8% of
		nd hospital noncontracted			ospital costs.				
12.	List service area	is in which reporting entity	is licensed to o	perate:			•		
				•	1				
				Name of S	ervice Area				
			NJ - Atlantic (
				-					
			NJ - Burlingto	n County					
				-					
				-					
				•					
				•					
				-					
				•					
			NJ - Ocean Co	ounty					
				•					
				•					
101	Daway ast as a	accata di an fan baaltbaaccin		·					NO
		custodian for health savin ovide the amount of custod							
		n administrator for health s							
		ovide the balance of the fu							
		aptive affiliates reported or							
14.2.	If the answer to	14.1 is yes, please provide	the following:						
		1	2	3	4	Assets S	upporting Rese	erve Credit	
			NAIC			5	6	7	
			NAIC Company	Domiciliary		Letters of	Trust		
		Company Name	Code		Reserve Credit		Agreements	Other	
15.	Dravida tha falla	owing for individual ordinar							
13.	assumed or ced		y iiie iiisurance	policies (0.3.	business only)	TOI THE CUITER	t year (prior to	emsurance	
		mium Written							\$
	15.2 Total Incu	rred Claims							\$
	15.3 Number o	f Covered Lives							
					surance Include				
		Term (whether f							
		Whole Life (who				issue, "short i	torm app")		
		Variable Life (w						_	
		Universal Life (V							
		Variable Univers	sai Liie (With Or	without second	uary guarantee)	1			
16.		entity licensed or chartered							YES
16.1		eporting entity assume rein			-			the state of	
	domicile of the	reporting entity?							

FIVE-YEAR HISTORICAL DATA

FIVE-YEAR H	ISTORICAL [DATA			
	1	2	3	4	5
	2021	2020	2019	2018	2017
Balance Sheet (Pages 2 and 3)					
1. Total admitted assets (Page 2, Line 28)	35,521,972	20,635,587	24,641,339	8,312,890	
2. Total liabilities (Page 3, Line 24)	20,148,289	9,419,388	16,501,395	1,588	
3. Statutory minimum capital and surplus requirement	2,133,666	2,133,666	2,133,666	2,133,666	
4. Total capital and surplus (Page 3, Line 33)	15,373,683	11,216,199	8,139,944	8,311,302	
Income Statement (Page 4)					
5. Total revenues (Line 8)	74,089,498	53,816,315	24,357,882		
6. Total medical and hospital expenses (Line 18)	75,017,987	48,061,886	25,316,278		
7. Claims adjustment expenses (Line 20)	1,809,334	1,764,631	1,419,346		
8. Total administrative expenses (Line 21)		6,546,016	1,450,977		
9. Net underwriting gain (loss) (Line 24)	(17,697,337)	(550,045)	(6,914,892)		
10. Net investment gain (loss) (Line 27)	(69,876)	152,806	138,830	7,555	
11. Total other income (Lines 28 plus 29)		(36,755)			
12. Net income or (loss) (Line 32)					
Cash Flow (Page 6)			(2,12.3,23.3)		
13. Net cash from operations (Line 11)	(13.254.667)	(2.608.010)	977.717	5.374	
Risk-Based Capital Analysis		(=,:::,::)	,	-,	
14. Total adjusted capital	15.373.683	11.216.199	8.290.712	8.311.303	
15. Authorized control level risk-based capital		2,519,785			
Enrollment (Exhibit 1)	0,057,011	2,017,700	1,5 10,000	10,771	
16. Total members at end of period (Column 5, Line 7)	6 298	5 491	3 116		
17. Total members months (Column 6, Line 7)	74 119	62 955	31 920		
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3, and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
19. Total hospital and medical plus other non-health (Lines 18 plus Line					
19)	101.3	89.3	103.9		
20. Cost containment expenses					
21. Other claims adjustment expenses					
22. Total underwriting deductions (Line 23)					
23. Total underwriting gain (loss) (Line 24)					
Unpaid Claims Analysis (U&I Exhibit, Part 2B)	` ′	` ′	` ′		
24. Total claims incurred for prior years (Line 13, Col. 5)	9.542.167	3.809.798			
25. Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]					
Investments in Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29. Affiliated short-term investments (subtotal included in Sch. DA Verification, Col. 5, Line 10)					
30. Affiliated mortgage loans on real estate					
31. All other affiliated					
32. Total of above Lines 26 to 31					
33. Total investment in parent included in Lines 26 to 31 above					

33. Total investment in parent included in Lines 26 to 31 above. — — — — — — — — NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3—Accounting Changes and Correction of Errors?

If no, please explain

SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS

	Allocated by States and Territories											
		1 Direct Business Only										
			[2	3	4	5	6	7	8	9	10
	States, Etc.		Active Status (a)	Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Federal Employees Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	Property / Casualty Premiums	Total Columns 2 Through 7	Deposit-Type Contracts
		AL	N									
		AK AZ	N									
		AZ AR	N									
		CA	N									
		CO	N									
		CT	N									
8.	Delaware	DE	N									
		DC	N									
		FL	N									
		GA	N									
		HI ID	N									
		IL	N						***************************************			
		IN	N									
		IA	N									
		KS	N									
		KY	N									
		LA	N									
		ME	N									
		MD	N									
		MA	N									
		MI MN	N									
		MS	N									
		MO	N									
		MT	N									
		NE	N									
		NV	N									
		NH	N									
	New Jersey		L		72,953,922						72,953,922	
		NM NY	N									
		NY NC	N									
		ND	N									
		OH	N									
		OK	N									
38.	Oregon	OR	N									
		PA	N									
		RI	N									
		SC	N									
		SD TN	N									
		TX	L		1,174,453						1,174,453	
		UT	N		1,174,400						1,1/4,433	
		VT	N									
		VA	N									
48.	Washington	WA	N									
	•	WV	N									
		WI	N									
	Wyoming		N									
	American Samoa Guam		N									
	Puerto Rico		N									
	US Virgin Islands		N									
	Northern Mariana Islands		N									
		CAN	N									
58.	Aggregate Other Alien	OT	XXX									
	Subtotal		XXX		74,128,375						74,128,375	
	Reporting entity contributions		VVVV									
	for Employee Benefit Plans		XXX		74 100 075						74100075	
	Total (Direct Business) of Write-Ins		XXX		74,128,375						74,128,375	
			vvv					1				
			XXX									
			XXX						***************************************			
	Summary of remaining write-		,									
	ins for Line 58 from overflow											
	page		XXX									
	Totals (Lines 58001 through							1				
	58003 plus 58998) (Line 58		VVV]				
	above)		XXX									

...2R – Registered - Non-domiciled RRGsQ – Qualified - Qualified or accredited reinsurer

⁽a) Active Status Counts

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG...

E - Eligible - Reporting entities eligible or approved to write surplus lines in the state...

N - None of the above - Not allowed to write business in the state...

(b) Explanation of basis of allocation by states, premiums by state, etc

Premiums are allocated based on the residence of the Member .55

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART

